-1 	|BT| (NP (NP (JJ Protective) (NN effect) (NN dioscin) (JJ alcohol-induced) (NN liver) (NN injury))) |ET| |BS|242:A03.620 751:D02.033.375 822:D02.033|ES| 19:1 75:1 836:1 2416:1 2672:1 2909:1 2910:1
-1 	|BT| (NP (NP (NN Protein) (NN kinase) (JJ potential) (JJ chemotherapeutic) (NN target) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 151:E02.319 823:D08.811.913.696.620.682.700.150.125|ES| 17:1 18:1 19:1 160:1 470:1 827:1 1762:1 2911:1
-1 	|BT| (S (NP (NN Pterostilbene)) (VP (VBZ inhibits) (NP (NP (NP (JJ colorectal) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (NP (NN colon) (NN carcinogenesis)) (PP (IN via) (NP (NN suppression) (JJ multiple) (NN signal) (NN transduction) (NN pathway) (JJ azoxymethane-treated) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 52:E02 122:C14.280.383 126:G02.111.087.800 132:D02.172.080 824:C04.834.020|ES| 10:1 14:1 17:1 19:1 52:1 113:1 207:1 383:1 596:1 615:1 649:1 859:1 1431:1 1725:1 2453:1 2793:1 2912:1 2913:1 2914:1 2915:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (JJ objective)) (VP (VBP investigate) (SBAR (IN whether) (S (NP (NP (NN polymorphism) (JJ putative) (NN influence) (NN fluorouracil/oxaliplatin) (NN activity)) (VBN associated) (JJ clinical) (NN outcome) (NN patient)) (VP (VBD advanced) (NP (NP (JJ colorectal) (NN cancer)) (VP (VBN treated) (NP (NP (JJ first-line) (NN oxaliplatin)) (, ,) (NP (JJ folinic) (NN acid)) (, ,) (NP (NN fluorouracil) (JJ palliative) (NN chemotherapy)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 151:E02.319 307:G05.365.795 415:F01.658.500 560:D03.383.742.698.875.404 825:D03.438.733.631.400.800.350.450 826:F01.752.609|ES| 2:1 17:1 18:1 19:1 84:1 104:1 120:1 169:1 221:1 399:1 459:1 495:1 547:1 687:1 691:1 867:1 918:1 997:1 1060:1 1099:1 1275:1 2490:1 2543:1 2916:1 2917:1 2918:1 2919:1 2920:1
-1 	|BT| (NP (NP (NP (NN Ras) (NN pathway) (NN activation) (JJ hepatocellular) (NN carcinoma) (JJ anti-tumoral) (NN effect)) (NP (VBN combined) (JJ sorafenib) (NN rapamycin) (FW vivo)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 104:C04.557.470.200.025.255 827:D02.540.505.760|ES| 19:1 75:1 164:1 225:1 303:1 304:1 378:1 383:1 1775:1 2063:1 2921:1 2922:1
-1 	|BT| (S (S (NP (JJ Regular) (NN aspirin) (NN use) (NN diagnosis)) (VP (VBD associated) (NP (JJR lower) (NN risk) (JJ colorectal) (JJ cancer-specific) (NN mortality)) (PP (IN among) (NP (NP (NN participant) (JJ primary) (NN tumor) (JJ overexpressed) (NN COX-2)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 0.39)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.20-0.76)))) (-RRB- -RRB-)))))) (, ,) (IN whereas) (S (NP (NN aspirin) (NN use)) (VP (VBD associated) (NP (JJR lower) (NN risk)) (PP (IN among) (NP (NP (JJ primary) (NN tumor) (JJ weak) (JJ absent) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 1.22)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.36-4.18)))) (-RRB- -RRB-))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 828:Z01.107.757.235|ES| 2:1 7:1 10:1 14:1 17:1 19:1 25:1 76:1 115:1 117:1 169:1 171:1 217:1 338:1 344:1 367:1 369:1 372:1 374:1 1037:1 1372:1 1659:1 2487:1 2508:1 2509:1 2511:1 2923:1 2924:1 2925:1 2926:1 2927:1 2928:1 2929:1 2930:1
-1 	|BT| (S (NP (NNS Results)) (NP (ADJP (FW vitro) (FW vivo)) (NN bioassay)) (ADVP (RB clearly)) (VP (VBP suggest) (SBAR (S (NP (NN beta-ionone)) (VP (MD could) (VP (VBD developed) (NP (NN prevention) (NN treatment) (NN colon) (NN cancer)))))))) |ET| |BS|52:E02 106:E05.091|ES| 18:1 19:1 113:1 216:1 378:1 546:1 702:1 796:1 908:1 1165:1 1474:1 2838:1 2931:1 2932:1
-1 	|BT| (FRAG (NP (NNS RESULTS)) (: :) (NP (NP (NN Liver) (NN tumor) (NN mass)) (NP (NP (NP (JJR lower) (NN pravastatin) (NN group)) (PRN (-LRB- -LRB-) (NP (NN PG)) (-RRB- -RRB-))) (NP (NP (NP (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NN CG)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN estimated) (NN number) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR <) (NP (CD 0.004)))) (-RRB- -RRB-))) (NP (NP (NN liver) (NN weight/body) (NN weight) (NN ratio)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (NP (QP (JJR <) (CD 0.04)))) (-RRB- -RRB-))))))) |ET| |BS|242:A03.620 515:C04.588.274.623 616:E05.318.780.074 653:C23.888.144 817:D02.455.426.559.847.638.930 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 104:1 117:1 289:1 312:1 646:1 710:1 836:1 2300:1 2399:1 2721:1 2804:1 2933:1 2934:1 2935:1 2936:1 2937:1 2938:1 2939:1 2940:1 2941:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN Silibinin) (NN feeding)) (VP (VBD showed) (NP (NP (ADJP (NP (JJ dose-dependent) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)) (JJR stronger)) (NN efficacy) (NN pretreatment)) (CC versus) (NP (NN posttreatment) (NNS regimen))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 532:E02.183|ES| 19:1 78:1 104:1 113:1 132:1 295:1 710:1 1881:1 1983:1 2304:1 2531:1 2533:1 2824:1 2942:1 2943:1 2944:1 2945:1
-1 	|BT| (S (NP (NNP Resveratrol)) (VP (VBZ interferes) (NP (NP (JJ N-nitrosodiethylamine-induced) (JJ hepatocellular) (NN carcinoma)) (JJ early) (JJ advanced) (NN stage) (JJ male) (JJ Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 303:1 304:1 849:1 997:1 1128:1 1129:1 1402:1 2603:1 2946:1 2947:1 2948:1
-1 	|BT| (S (S (NP (NN Rimonabant)) (VP (VBZ inhibits) (NP (JJ human) (NN colon) (NN cancer) (NN cell) (NN growth)))) (VP (VBZ reduces) (NP (NN formation) (JJ precancerous) (NN lesion) (NN mouse) (NN colon)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 341:C04.834|ES| 18:1 19:1 36:1 43:1 52:1 94:1 102:1 113:1 142:1 615:1 1130:1 1131:1 2949:1
-1 	|BT| (NP (NP (NN Role) (NN Fas/FasL) (NN pathway) (NN combination) (NN therapy) (NN interferon-alpha) (NN fluorouracil) (JJ hepatocellular) (NN carcinoma) (NN vitro))) |ET| |BS|15:F01.829.316.616 104:C04.557.470.200.025.255 356:D12.644.276.374.440.890.250 560:D03.383.742.698.875.404 618:E02.186|ES| 19:1 130:1 216:1 303:1 304:1 383:1 530:1 1198:1 2187:1 2919:1 2950:1
-1 	|BT| (NP (NP (NNP Saffron)) (: :) (NP (JJ potential) (NN candidate) (JJ novel) (JJ anticancer) (NN drug) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|67:D26 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 701:B01.650.940.800.575.100.549.500|ES| 19:1 104:1 191:1 303:1 304:1 827:1 891:1 1243:1 1880:1 2951:1
-1 	|BT| (NP (NP (NNP Sesamin)) (, ,) (NP (JJ lipid-soluble) (NN lignan)) (, ,) (S (NP (CD one) (NN agent)) (VP (VBZ belongs) (NP (SBAR (S (NP (NP (NN class) (NNS phytoestrogens)) (, ,) (NP (NP (VBN isolated) (NN sesame)) (PRN (-LRB- -LRB-) (NP (NN Sesamum) (NN indicum)) (-RRB- -RRB-))) (, ,)) (VP (VBN linked) (NP (NN prevention) (NN hyperlipidemia))))) (, ,) (NP (NP (NN hypertension)) (, ,) (NP (NN carcinogenesis) (JJ unknown) (NN mechanism))))))) |ET| |BS|33:C04.697.098 621:D02.455.426.559.389.140.450 659:D10 766:C18.452.584.500.500 830:B01.650.940.800.575.100.583.690.750 831:D27.505.696.399.472.277.540.500 832:C14.907.489|ES| 2:1 10:1 14:1 19:1 162:1 207:1 728:1 1010:1 1363:1 1474:1 1653:1 2182:1 2313:1 2692:1 2814:1 2952:1 2953:1 2954:1 2955:1 2956:1 2957:1 2958:1 2959:1
-1 	|BT| (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (JJ molecular) (NN therapy) (JJ non-small-cell) (NN lung) (NN cancer))) |ET| |BS|52:E02 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 375:Z01.639.100|ES| 18:1 19:1 130:1 161:1 327:1 328:1 487:1 860:1 861:1 862:1 2960:1
-1 	|BT| (S (NP (NN Simvastatin)) (VP (VP (VBZ induces) (NP (NN apoptosis) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft))) (, ,) (VP (VBZ attenuates) (NP (JJ colitis-associated) (NN colon) (NN cancer) (NN mouse))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900|ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1
-1 	|BT| (S (NP (NN Sodium) (NN alginate)) (VP (VBZ prevents) (NP (NN progression) (JJ non-alcoholic) (NN steatohepatitis) (NN liver) (NN carcinogenesis) (JJ obese) (JJ diabetic) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 33:C04.697.098 242:A03.620 509:C06.552.241.519 564:C18.654.726.500|ES| 19:1 48:1 52:1 207:1 836:1 1791:1 2069:1 2468:1 2718:1 2962:1 2963:1 2964:1
-1 	|BT| (S (NP (NN Sulindac) (NNS NSAIDs)) (VP (ADVP (RB widely)) (NP (VBN studied) (NP (JJ potential) (JJ chemopreventive) (NN agent) (NN colon) (NN cancer))))) |ET| |BS|251:D02.455.426.559.847.486.875 796:D27.505.696.663.850.014.040.500 833:D27.505.696.706.018|ES| 18:1 19:1 113:1 401:1 728:1 827:1 1946:1 2369:1 2965:1 2966:1
-1 	|BT| (S (NP (NP (NN Supplementation) (JJ branched-chain) (NN amino) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BCAA)) (-RRB- -RRB-))) (VP (VBZ reduces) (NP (NP (NN risk) (NN liver) (NN cancer) (JJ cirrhotic) (NN patient)) (NP (JJ obese) (, ,) (NP (JJ associated) (NN improvement) (NN insulin) (NN resistance)))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500|ES| 2:1 10:1 14:1 18:1 19:1 120:1 142:1 169:1 171:1 836:1 1094:1 1275:1 2189:1 2359:1 2360:1 2364:1 2468:1 2967:1 2968:1 2969:1
-1 	|BT| (S (NP (NP (NP (NN Suppression) (JJ early) (NN stage) (JJ neoplastic) (NN transformation)) (JJ two-stage) (NN chemical) (NN hepatocarcinogenesis) (NN model)) (: :) (S (NP (NP (NN supplementation) (NN vanadium)) (, ,) (NP (JJ dietary) (NN micronutrient)) (, ,) (NP (NN limit) (NN cell) (NN proliferation))) (VP (VBZ inhibits) (NP (NP (NN formation) (NN 8-hydroxy-2)) ('' ')))) (: -)) (VP (NNS deoxyguanosines) (NP (NN DNA) (NNS strand-breaks) (NN liver) (JJ sprague-dawley) (NN rat)))) |ET| |BS|20:G03.495 32:C04.697.098.500 122:C14.280.383 183:G04.299.233.750 242:A03.620 595:G07.203.650.240 769:B01.050.150.900.649.865.635.505.700.750 834:D27.505.696.377.605.555 835:D27.505.696.377.605 836:G05.355.180.210 837:D01.268.556.920 838:E05.599.495|ES| 2:1 19:1 43:1 72:1 94:1 104:1 299:1 615:1 666:1 836:1 849:1 893:1 900:1 1128:1 1129:1 1384:1 2124:1 2567:1 2594:1 2797:1 2970:1 2971:1 2972:1 2973:1 2974:1 2975:1 2976:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (NP (VBN indicated) (NN nifuroxazide)) (VP (MD could) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN tumor) (NN metastasis)) (S (VP (VBG mediating) (NP (NP (NN Stat3)) (NN pathway))))))) (VP (MD might) (NP (JJ therapeutic) (JJ potential) (NN treatment) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383|ES| 2:1 7:1 19:1 101:1 245:1 383:1 541:1 546:1 761:1 798:1 806:1 827:1 908:1 1370:1 1537:1 1538:1 1541:1 2646:1 2820:1 2977:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP provide) (SBAR (S (NP (NP (NN evidence) (NN plant) (NN flavonoid) (NN fisetin)) (VP (VBP induce) (NP (NN apoptosis)))) (VP (VBP suppress) (NP (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN inhibition) (NN COX2)) (: -) (NP (NN Wnt/EGFR/NF-kappaB-signaling) (NN pathway)))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 43:F01.145.544 45:G07.700.320.249 147:G02.149.115.800.925 210:D12.776.260.600 328:B01.650 534:D03.383.663.283.266.450|ES| 2:1 18:1 19:1 38:1 89:1 94:1 102:1 103:1 113:1 243:1 383:1 711:1 1098:1 1537:1 1538:1 1886:1 2441:1 2978:1 2979:1 2980:1
-1 	|BT| (S (NP (VBN Targeted) (NN disruption) (JJ Nemo-like) (NN kinase)) (VP (VBZ inhibits) (NP (NN tumor) (NN cell) (NN growth) (JJ simultaneous) (NN suppression) (NN cyclin) (NN D1) (NN CDK2) (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|8:C04 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 215:D12.644.360.262.150.100 469:D08.811.913.696|ES| 7:1 19:1 36:1 94:1 102:1 303:1 304:1 470:1 615:1 743:1 744:1 1602:1 2453:1 2981:1 2982:1 2983:1 2984:1
-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP investigate) (NP (NP (NP (NP (JJ molecular) (NN mechanism) (JJ chemopreventive) (NN effect)) (JJ folic) (NN acid) (NN tributyrin)) (ADVP (RB alone))) (NN combination) (NN rat) (NN hepatocarcinogenesis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 624:D27.505.696.706.018 839:D03.438.733.631.400|ES| 19:1 75:1 131:1 161:1 162:1 241:1 459:1 530:1 691:1 849:1 900:1 1275:1 1567:1 1946:1 2985:1 2986:1
-1 	|BT| (S (NP (DT The) (NN cyclooxygenase-2) (-LRB- -LRB-) (NN COX-2) (-RRB- -RRB-) (NN inhibitor) (NN celecoxib)) (VP (VBN approved) (NP (NP (NN drug) (NN clinic) (NN colon) (NN cancer) (NN chemoprevention)) (VP (VBN tested) (NP (NP (JJ chemopreventive) (JJ therapeutic) (NN efficacy)) (JJ various) (JJ clinical) (NN trial)))))) |ET| |BS|12:Z01.542.049 52:E02 67:D26 253:E02.319.162 349:D27.505.519.389.310.500 683:D27.505.519.389.310 684:D02.065.884.247 840:E01.789.800 841:E05.318.760.250.500 842:N02.278.035|ES| 10:1 14:1 18:1 19:1 61:1 76:1 84:1 113:1 191:1 380:1 541:1 691:1 870:1 1096:1 1946:1 2304:1 2343:1 2807:1 2987:1 2988:1 2989:1
-1 	|BT| (S (NP (DT The) (NNS data)) (VP (VBP provide) (NP (JJ additional) (NN evidence) (JJ potential) (NN use) (NN roxithromycin) (NN treatment) (JJ hepatocellular) (NN carcinoma) (NN prevention)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 843:D02.540.576.500.992.630|ES| 19:1 38:1 303:1 304:1 546:1 691:1 711:1 793:1 827:1 980:1 1474:1 1659:1 2990:1
-1 	|BT| (NP (NP (NP (DT The) (JJ Dual) (NN Inhibition) (NN RNA) (NN Pol)) (SBAR (S (NP (PRP I)) (NP (NN Transcription) (NNP PIM) (NN Kinase) (NNP New) (JJ Therapeutic) (NNP Approach) (NNP Treat) (NNP Advanced) (NNP Prostate) (NNP Cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 52:E02 209:G02.111.087.847 844:D08.811.913.696.445.735.270.750|ES| 19:1 469:1 515:1 691:1 1197:1 1412:1 1919:1 2280:1 2350:1 2703:1 2991:1 2992:1 2993:1 2994:1 2995:1 2996:1 2997:1
-1 	|BT| (S (NP (DT The) (JJ oncogenic) (NN kinase) (NN inhibitor) (NN sorafenib)) (ADVP (RB significantly)) (VP (VB prolong) (SBAR (S (NP (JJ median) (NN survival) (NN patient)) (VP (VBD advanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (, ,) (SBAR (IN although) (S (NP (NN response) (JJ disease-stabilizing) (JJ cytostatic)) (NP (QP (RB rather) (CD one)) (NN tumor) (NN regression))))))))) |ET| |BS|8:C04 50:M01.643 96:I03.784 104:C04.557.470.200.025.255 279:D27.888.569.100 288:C23.550.288 469:D08.811.913.696 845:D27.888.569.199 846:F01.393.784|ES| 2:1 7:1 10:1 14:1 19:1 120:1 124:1 274:1 303:1 304:1 380:1 441:1 470:1 494:1 691:1 953:1 997:1 1010:1 1170:1 1592:1 2063:1 2998:1 2999:1 3000:1 3001:1 3002:1
-1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ allows) (SBAR (S (NP (NN u)) (VP (VBP conclude) (SBAR (S (NP (JJ diosmin) (JJ dietary) (NN supplement)) (, ,) (VP (MD could) (VP (VBN used) (S (NP (JJ chemopreventive) (NN agent)) (VP (VBP prevent) (NP (NN hepatocarcinogenesis))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 557:D02.241.081.069.600.150 715:D03.383.663.283.266.450.260.222 847:G07.203.300.456|ES| 2:1 19:1 131:1 476:1 691:1 728:1 733:1 900:1 908:1 1307:1 1946:1 1968:1 2243:1 2594:1 2695:1 3003:1 3004:1
-1 	|BT| (NP (NP (NP (DT The) (JJ present) (NN study) (NN offer) (NN strategy) (JJ novel) (NN CUR) (NN analogue)) (, ,) (PRN (-LRB- -LRB-) (NP (NN 1E) (CD ,4) (NN E)) (-RRB- -RRB-)) (NP (NP (NP (NN -1,5-bis) (-LRB- -LRB-) (NN 2-bromophenyl) (-RRB- -RRB-) (NN penta-1,4-dien-3-one)) (PRN (-LRB- -LRB-) (NP (NN GL63)) (-RRB- -RRB-))) (, ,) (NP (VBN used) (JJ potential) (NP (NP (JJ therapeutic) (NN agent) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (ADVP (FW vitro) (FW vivo))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 131:1 216:1 303:1 304:1 378:1 441:1 476:1 541:1 691:1 728:1 827:1 891:1 1042:1 1114:1 1307:1 1380:1 3005:1 3006:1 3007:1 3008:1 3009:1 3010:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VBP investigate) (FRAG (NP (NP (JJ chemopreventive) (NN action) (JJ possible) (NN mechanism) (NN saffron) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN liver) (NN cancer) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 701:B01.650.940.800.575.100.549.500|ES| 10:1 14:1 18:1 19:1 162:1 409:1 459:1 691:1 836:1 849:1 1359:1 1497:1 1875:1 1946:1 1952:1 2013:1 2523:1 3011:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN study)) (VP (VBP evaluate) (NP (NP (NP (JJ anticancer) (NN potency) (NN mechanism) (JJ novel) (NN difluorodiarylidenyl) (NN piperidone)) (PRN (-LRB- -LRB-) (NP (NN H-4073)) (-RRB- -RRB-))) (S (NP (NP (NN N-hydroxypyrroline) (NN modification)) (PRN (-LRB- -LRB-) (NP (NN HO-3867)) (-RRB- -RRB-))) (NP (JJ human) (JJ ovarian) (NN cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 179:D01.248.497.300.459.700 225:E05.337 259:D12.776.395.240.150.500 848:D03.383.621.808|ES| 10:1 14:1 18:1 19:1 36:1 131:1 162:1 691:1 890:1 891:1 1763:1 1880:1 2374:1 2796:1 3011:1 3012:1 3013:1 3014:1 3015:1 3016:1
-1 	|BT| (NP (NP (NP (DT The) (NN rate) (NN proliferation) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN reduced) (JJ treated) (NN gamma-secretase) (NN inhibitor) (NN dibenzazepine)) (VP (VBP inhibit) (NP (NP (NN Notch) (NN signaling) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD directed) (NP (NN Notch))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 117:D13.150.650.700 122:C14.280.383 125:D08.811.277.656.300.032 212:E01.370.225.500.385.500 792:A11.251.210.190.475|ES| 18:1 19:1 36:1 41:1 94:1 113:1 195:1 256:1 299:1 380:1 452:1 515:1 691:1 750:1 1099:1 1370:1 1866:1 3017:1 3018:1 3019:1 3020:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBD indicated) (SBAR (S (NP (NN 6-MSITC)) (VP (VBD exerted) (NP (NP (NP (JJ chemopreventive) (NN effect)) (JJ present) (JJ short-term) (NN colon) (NN carcinogenesis) (NN bioassay)) (, ,) (NP (NP (NN alteration) (NN cell) (NN proliferation) (NN activity) (NN drug)) (VP (VBG metabolizing) (NP (NN enzyme) (NN level)))))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 67:D26 106:E05.091 212:E01.370.225.500.385.500 624:D27.505.696.706.018 649:E01.370.225.124.200 849:G08.686.785.760.769.490.500|ES| 2:1 19:1 75:1 94:1 101:1 113:1 191:1 207:1 249:1 299:1 399:1 691:1 951:1 1307:1 1541:1 1946:1 2102:1 2388:1 2931:1 3021:1 3022:1 3023:1
-1 	|BT| (S (NP (DT The) (JJ selective) (NN EGFR) (NN inhibitor) (NN Gefitinib)) (VP (VBD found) (S (VP (VBP prevent) (NP (NN hepatocarcinogenesis) (NN rat) (JJ cirrhotic) (NN liver)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 37:1 187:1 380:1 691:1 733:1 836:1 849:1 900:1 1749:1 2968:1 3024:1
-1 	|BT| (S (NP (DT The) (NN study)) (VP (VBD suggested) (SBAR (S (NP (NN HO-3867)) (VP (MD may) (NP (NP (JJ useful) (JJ safe) (JJ effective) (JJ anticancer) (NN agent)) (JJ ovarian) (NN cancer) (NN therapy))))))) |ET| |BS|52:E02|ES| 18:1 19:1 130:1 131:1 491:1 691:1 728:1 925:1 1036:1 1639:1 1763:1 1880:1 2737:1 3016:1
-1 	|BT| (S (NP (DT The) (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (MD may) (SBAR (S (NP (JJ unique) (NN property) (VBG providing) (NN protection) (JJ DENA-induced) (JJ oxidative) (NN stress)) (VP (MD could) (VP (VB contribute) (NP (NN chemoprevention) (JJ experimental) (NN hepatocarcinogenesis)))))))) |ET| |BS|253:E02.319.162 554:D02.654.442.200 716:G03.495.710 803:D01.248.497.158.845 804:D09.698|ES| 19:1 263:1 450:1 491:1 691:1 841:1 870:1 900:1 908:1 1469:1 2522:1 2583:1 2734:1 2839:1 2840:1 2841:1 2842:1 3025:1 3026:1
-1 	|BT| (S (NP (DT The) (NN theme) (NN study)) (VP (VBP evaluate) (SBAR (S (NP (JJ therapeutic) (NN efficacy)) (VP (VBD nanoencapsulated) (FRAG (NP (JJ flavonoidal) (NN quercetin)) (-LRB- -LRB-) (NP (NP (NP (CD 3,5,7,3) ('' ') (NN ,4)) ('' ') (PRN (: -) (NP (NP (NN pentahydroxy) (NN flavone)) (, ,) (NP (NN QC))) (-RRB- -RRB-))) (S (VP (VBG combating) (NP (JJ DEN-induced) (NN hepatocarcinogenesis) (NN rat))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 533:D03.383.663.283.266.450.284.777 850:D03.383.663.283.266.450.260 851:J01.897.608|ES| 2:1 10:1 14:1 19:1 131:1 541:1 691:1 849:1 890:1 900:1 1884:1 2304:1 2735:1 3027:1 3028:1 3029:1 3030:1 3031:1 3032:1 3033:1
-1 	|BT| (NP (NP (JJ Therapeutic) (NN effect) (JJ multi-targeted) (NN imidazolium) (NN compound) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255|ES| 19:1 75:1 303:1 304:1 2433:1 2993:1 3034:1 3035:1
-1 	|BT| (S (NP (NP (NN Therapy)) (VP (VBG targeting) (NP (NN Vav3) (NN combination) (NN docetaxel)))) (VP (MD may) (NP (JJ practical) (NN implication) (NN managing) (JJ castration-resistant) (NN prostate) (NN cancer)))) |ET| |BS|618:E02.186 852:C04.588.945.440.770.500|ES| 18:1 19:1 77:1 85:1 491:1 530:1 616:1 3036:1 3037:1 3038:1 3039:1 3040:1 3041:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (JJ genetic) (NN amplification) (NN TYMS) (JJ major) (NN mechanism) (NN 5-FU) (NN resistance)) (PP (FW vivo) (NP (NP (JJ important) (NN implication) (NN management) (JJ colorectal) (NN cancer) (NN patient)) (JJ recurrent) (NN disease)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 288:C23.550.288 392:G05.355.315.250 496:C23.550.291.937 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 853:N04.590.607|ES| 17:1 18:1 19:1 85:1 120:1 162:1 378:1 462:1 792:1 793:1 796:1 864:1 902:1 921:1 998:1 1094:1 1753:1 2308:1 3042:1 3043:1
-1 	|BT| (NP (DT These) (VBG finding) (S (VP (VBP confirm) (NP (NN hypothesis) (NN ODC) (NN polymorphism) (JJ genetic) (NN marker) (NN colon) (NN cancer) (NN risk))) (, ,) (NP (NP (NP (NN support) (NN use) (NN ODC) (NN inhibitor) (NN aspirin)) (, ,) (NP (NP (JJ nonsteroidal) (JJ antiinflammatory) (NN drug)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))) (, ,)) (NN combination) (NN strategy) (NN colon) (NN cancer) (NN prevention)))) |ET| |BS|61:E05.318.740.600.800 149:G05.360.340.024.340.364.875.890 158:D23.101 307:G05.365.795 670:D02.455.426.559.389.657.410.595.176 796:D27.505.696.663.850.014.040.500|ES| 2:1 10:1 14:1 18:1 19:1 113:1 171:1 191:1 380:1 530:1 534:1 792:1 864:1 927:1 1060:1 1114:1 1364:1 1474:1 1659:1 2477:1 2487:1 2697:1 2966:1 3044:1 3045:1 3046:1
-1 	|BT| (PP (DT These) (S (VP (VBG finding) (S (VP (VBP suggest) (SBAR (S (NP (NN sulindac)) (VP (MD may) (NP (NP (JJ effective) (NN agent) (NN colon) (NN cancer) (NN prevention)) (NP (JJ human) (JJ low) (NN 15-PGDH)))))))) (, ,) (S (NP (NN use)) (MD may) (ADVP (RB also)) (VP (VBN associated) (NP (JJ inflammatory) (NN lesion) (NN colon))))))) |ET| |BS|46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 251:D02.455.426.559.847.486.875|ES| 2:1 5:1 18:1 19:1 36:1 113:1 133:1 169:1 491:1 531:1 728:1 792:1 796:1 869:1 927:1 1131:1 1474:1 1639:1 1659:1 2430:1
-1 	|BT| (NP (NP (DT These) (NN observation) (NN show)) (, ,) (NP (JJ first) (NN time)) (, ,) (S (NP (NP (NN CP-31398) (NN posse) (JJ significant) (JJ dose-dependent) (JJ chemopreventive) (NN activity)) (JJ well-established) (NN colon) (NN cancer) (NN model) (NN combination) (JJ low-dose) (NN CP-31398) (NN celecoxib)) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NN colon) (NN cancer) (JJ chemopreventive) (NN efficacy))))) |ET| |BS|322:G01.910 429:N04.761.559.590.900 430:E05.581.249 684:D02.065.884.247|ES| 2:1 18:1 19:1 72:1 113:1 124:1 135:1 385:1 399:1 429:1 530:1 792:1 816:1 1081:1 1477:1 1770:1 1946:1 2304:1 2807:1 2824:1 3047:1 3048:1 3049:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (ADVP (RB also)) (VP (VBP support) (NP (NN role) (NNP BMX) (JJ potential) (NN drug) (NN candidate) (NN use) (NN combination) (NN cisplatin) (NN treatment) (JJ human) (NN lung) (NN cancer))))) |ET| |BS|15:F01.829.316.616 52:E02 55:B01.050.150.900.649.801.400.112.400.400 67:D26 375:Z01.639.100 498:D01.210.375|ES| 5:1 18:1 19:1 31:1 36:1 101:1 191:1 328:1 530:1 546:1 792:1 827:1 1243:1 1364:1 1659:1 1761:1 3050:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VP (VBP indicate) (SBAR (S (NP (NP (NN chitin)) (, ,) (NP (NN chitosan) (JJ related) (NN compound))) (VP (VBP exert) (NP (NP (JJ unequivocal) (JJ chemopreventive) (NN effect)) (NP (JJ heterocyclic) (JJ amine-induced) (NN hepatocarcinogenesis))))))) (, ,) (SBAR (S (NP (NN effect) (NN organ)) (VP (MD may) (SBAR (S (NP (NN tissue) (JJ specific) (JJ possible) (JJ inhibitory) (NN action) (JJ mammary) (NN gland)) (VP (VBD offset) (NP (NN promotion) (NN colon) (NN lesion) (NN development))))))))))) |ET| |BS|46:A03.556.124.526.356 98:A10 609:A01.236.249 624:D27.505.696.706.018 854:D05.750.078.139.500 855:D05.750.078.139 856:D02.092|ES| 2:1 19:1 35:1 75:1 101:1 113:1 272:1 419:1 491:1 540:1 592:1 792:1 900:1 1131:1 1359:1 1382:1 1479:1 1946:1 2013:1 2248:1 2337:1 2429:1 2433:1 2843:1 3051:1 3052:1 3053:1 3054:1 3055:1 3056:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NNP Valerian) (VP (VBP exhibit) (S (NP (JJ inhibitory) (NN effect) (NN rat) (NN hepatocarcinogenesis)) (VP (VBG inhibiting) (NP (JJ oxidative) (NN DNA) (NN damage)))) (, ,) (S (VP (VBG suppressing) (NP (NP (NN cell) (NN proliferation)) (VP (VBG inducing) (NP (NP (NP (NN apoptosis) (NN GST-P)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN focus) (VBG activating) (NN GABA) (-LRB- -LRB-) (NN A) (-RRB- -RRB-) (JJ R-mediated) (NN signaling)))))))))))) |ET| |BS|39:G04.299.139.160 69:G02.111.087.800 122:C14.280.383 175:J01.897.280.500.269 183:G04.299.233.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 526:G05.355.180 599:M01.526.799.500 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 859:D02.241.081.114.500.350|ES| 2:1 10:1 14:1 19:1 69:1 75:1 89:1 94:1 101:1 195:1 299:1 587:1 666:1 792:1 849:1 880:1 900:1 1431:1 1479:1 1848:1 1864:1 1958:1 2250:1 2429:1 2583:1 3057:1 3058:1 3059:1 3060:1 3061:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP provide) (SBAR (S (NP (JJ preclinical) (NN evidence)) (VP (VBP continue) (NP (NP (NN development) (NN alantolactone) (NN STAT3) (NN inhibitor)) (JJ potential) (JJ therapeutic) (NN agent) (NN breast) (NN cancer)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 82:D12.644.360.024.342.300|ES| 18:1 19:1 23:1 35:1 38:1 101:1 251:1 380:1 541:1 711:1 728:1 792:1 827:1 1494:1 2686:1 3062:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (NP (NN show) (NN Cx32) (NN luteolin) (JJ suppressive) (NN role)) (NN inflammation) (, ,) (NN fibrosis) (NN hepatocarcinogenesis) (NN NASH) (NN progression)) (, ,) (S (VP (VBG suggesting) (NP (JJ potential) (JJ therapeutic) (NN application) (NNP NASH)))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 52:E02 525:C23.550.470 691:C23.550.355 704:D03.383.663.283.266.450.260.555|ES| 2:1 19:1 31:1 48:1 101:1 165:1 429:1 541:1 792:1 827:1 900:1 949:1 1009:1 1974:1 2547:1 3063:1 3064:1 3065:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN simvastatin)) (VP (MD could) (NP (NP (JJ potential) (JJ chemopreventive) (JJ therapeutic) (NN agent)) (NP (NP (NNP CAC)) (NP (ADVP (RB well)) (NP (ADJP (FW de) (FW novo)) (NN colon) (NN cancer))))))))))) |ET| |BS|52:E02 754:D02.455.426.559.847.638.400.900 860:Z01.107.567.875.500.200 861:Z01.542.315|ES| 18:1 19:1 101:1 113:1 541:1 728:1 787:1 792:1 796:1 827:1 908:1 1946:1 2679:1 3066:1 3067:1 3068:1
-1 	|BT| (S (NP (NNS Thiazolidinediones)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (NN hepatitis) (NN B) (JJ virus-transgenic) (NN mouse) (NN peroxisome) (JJ proliferator-activated) (NN receptor) (JJ gamma-independent) (NN regulation) (NN nucleophosmin)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 99:B01.050.050.136.500 122:C14.280.383 142:I01.880.604 719:D12.776.826.239.588 862:D02.886.675.933 863:B04.280.375.650.425|ES| 19:1 52:1 186:1 438:1 763:1 900:1 1370:1 1801:1 1887:1 2048:1 3069:1 3070:1 3071:1 3072:1
-1 	|BT| (S (NP (NN Thioredoxin) (NN reductase) (CD 1)) (VP (VBZ protects) (VP (ADVP (RB chemically)) (VBN induced) (NN hepatocarcinogenesis) (PP (IN via) (NP (NN control) (JJ cellular) (NN redox) (NN homeostasis)))))) |ET| |BS|41:A11 152:G07.700.345 864:D08.811.682.667.750.500 865:G02.149.767.650|ES| 19:1 96:1 98:1 289:1 412:1 500:1 596:1 900:1 1863:1 2581:1 3073:1 3074:1 3075:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (VP (VBP result) (NP (NN support) (JJ future) (NN utilization) (NN decorin) (NN antitumor) (NN agent) (NN liver) (NN cancer)))) |ET| |BS|354:I01.320 375:Z01.639.100 660:D27.505.954.248 708:D12.776.395.650.750.625|ES| 2:1 18:1 19:1 101:1 728:1 836:1 1190:1 1364:1 1691:1 2244:1 2901:1 3076:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PKCbetaII) (JJ important) (NN target) (NN colon) (NN cancer) (NN chemoprevention) (JJ PKCbeta-selective) (NN inhibitor) (NN enzastaurin)) (VP (MD may) (VP (VB represent) (NP (NP (JJ effective) (JJ chemopreventive) (NN agent) (NN patient)) (JJ high) (NN risk) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 61:E05.318.740.600.800 253:E02.319.162 866:D08.811.913.696.620.682.700.725.049 867:D08.811.913.696.620.682.700.725.049 868:M01.380.600|ES| 2:1 18:1 19:1 113:1 120:1 160:1 171:1 178:1 380:1 491:1 728:1 799:1 870:1 902:1 1639:1 1691:1 1946:1 2855:1 3077:1 3078:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NP (NN combination) (NN As2O3) (NN Ad-PML) (JJ synergistic) (JJ inhibitory) (NN effect)) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (, ,) (S (VP (ADVP (RB possibly)) (VBG resulting) (NP (NN regulation) (JJ apoptotic) (NN gene) (NN expression)))) (VP (VBD enhanced) (NP (NNP HCC) (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255 140:G05.355.315|ES| 2:1 9:1 10:1 14:1 19:1 75:1 89:1 115:1 303:1 304:1 384:1 385:1 438:1 441:1 530:1 1548:1 1691:1 2012:1 2223:1 2429:1 3079:1 3080:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN study)) (VP (VBP show) (NP (JJ myrtenal) (NN ability) (VBP suppress) (JJ hepatocellular) (NN carcinoma) (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 385:F02.784.629.131|ES| 2:1 19:1 131:1 303:1 304:1 429:1 849:1 1300:1 1691:1 2441:1 2682:1
-1 	|BT| (NP (NP (NNP Thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NN dihydropyrimidine) (NN dehydrogenase) (NN expression)) (, ,) (NP (JJ histological) (NN tumour) (NN regression) (JJ 5-FU-based) (JJ neo-adjuvant) (JJ chemoradiotherapy) (JJ rectal) (NN cancer))) |ET| |BS|8:C04 333:D01.045 560:D03.383.742.698.875.404 561:E02.186.079.500 713:D08.811.913.555.500.862 846:F01.393.784 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350|ES| 2:1 18:1 19:1 66:1 115:1 1011:1 1986:1 1987:1 1988:1 1989:1 3002:1 3081:1 3082:1 3083:1 3084:1 3085:1 3086:1
-1 	|BT| (S (NP (NNP Thymoquinone)) (VP (VBZ reduces) (SBAR (S (NP (NN mouse) (NN colon) (NN tumor) (NN cell) (NN invasion)) (VP (VBZ inhibits) (NP (NN tumor) (NN growth) (JJ murine) (NN colon) (NN cancer) (NN model))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 51:C04.588.274.476.411.307.180 122:C14.280.383|ES| 7:1 18:1 19:1 52:1 72:1 94:1 102:1 113:1 142:1 615:1 620:1 627:1 3087:1
-1 	|BT| (NP (NP (S (VP (TO To) (ADVP (RBR better)) (VP (VB understand) (NP (NP (JJ anticancer) (NN activity) (NNP Levamisole)) (PRN (-LRB- -LRB-) (NP (NNP LMS)) (-RRB- -RRB-)))))) (, ,) (NP (NP (NN serf) (JJ adjuvant) (NN colon) (NN cancer) (NN therapy) (NN combination) (NN 5-Fluorouracil)) (, ,) (NP (NP (NN study) (NN analysis) (NNP LMS) (POS ')) (NN ability)) (S (VP (VBP induce) (NP (NP (NN apoptosis) (NN growth) (NN arrest)) (NP (VBN cultured) (JJ human) (JJ micro) (: -) (NP (JJ macrovascular) (JJ endothelial) (NN cell) (PRN (-LRB- -LRB-) (NP (NNS ECs)) (-RRB- -RRB-)) (NN fibroblast))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 385:F02.784.629.131 560:D03.383.742.698.875.404 618:E02.186 685:D27.505.696.477.067 687:D26.650.064 871:D02.886.675.346 872:A11.329.228 873:A11.436.275|ES| 2:1 10:1 14:1 18:1 19:1 36:1 89:1 94:1 102:1 113:1 130:1 131:1 243:1 399:1 530:1 602:1 661:1 828:1 829:1 882:1 904:1 1232:1 1300:1 1489:1 1880:1 2213:1 2404:1 2479:1 3088:1 3089:1 3090:1 3091:1 3092:1 3093:1
-1 	|BT| (S (S (VP (TO To) (VP (VB improve) (NP (JJ clinical) (NN outcome))))) (, ,) (NP (NN investigation) (JJ potential) (NN bortezomib) (NN therapy) (NN thyroid) (NN cancer)) (ADVP (RB clearly)) (VP (VBD warranted))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 225:E05.337 675:D01.029.260.110.500|ES| 2:1 18:1 19:1 84:1 130:1 547:1 827:1 828:1 969:1 1497:1 2466:1 2816:1 2838:1 3094:1
-1 	|BT| (S (VP (ADVP (RB Together)) (, ,) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NN silibinin)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN SW480) (NN tumor)) (VP (VBG carrying) (NP (JJ mutant) (NN APC) (NN gene) (NN down-regulating) (NN CDK8) (NN beta-catenin) (NN signaling)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (NP (JJ effective) (NN agent) (NN CRC))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 247:G01.374.676.530 351:A17.360|ES| 2:1 7:1 9:1 11:1 19:1 60:1 102:1 195:1 218:1 245:1 615:1 728:1 796:1 811:1 850:1 908:1 927:1 1639:1 2635:1 3095:1 3096:1 3097:1 3098:1
-1 	|BT| (S (NP (NN Tongue) (NN cancer) (NN prevention) (NN study)) (VP (VBD conducted) (NP (NP (JJ zinc-deficient) (NN rat)) (NP (ADJP (RB previously) (VBN exposed)) (NN tongue) (NN carcinogen) (NN celecoxib) (NN treatment))) (VP (PP (IN without) (NP (NN zinc) (NN replenishment))) (, ,) (NP (NP (NN zinc) (NN replenishment)) (ADVP (RB alone)))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 684:D02.065.884.247 874:D01.268.556.940 875:A03.556.500.885 876:F01.145|ES| 2:1 18:1 19:1 131:1 241:1 546:1 849:1 1195:1 1474:1 1527:1 2125:1 2807:1 3099:1 3100:1 3101:1 3102:1 3103:1 3104:1 3105:1
-1 	|BT| (S (NP (NP (NP (NN Treatment) (NN mouse) (NN EGFR-inhibitor)) (PRN (-LRB- -LRB-) (NP (NN EGFRi)) (-RRB- -RRB-))) (, ,) (NP (NN Canertinib)) (, ,)) (VP (VBP 1h) (ADJP (JJ post-APAP)) (VP (VBD resulted) (NP (NP (JJ robust) (NN inhibition) (NN EGFR-activation) (JJ striking) (NN reduction)) (JJ APAP-induced) (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 52:E02 242:A03.620 661:D02.065.199.092.040 877:N03.540.571.608|ES| 2:1 10:1 14:1 19:1 52:1 103:1 370:1 594:1 836:1 2416:1 3106:1 3107:1 3108:1 3109:1 3110:1 3111:1 3112:1 3113:1 3114:1 3115:1
-1 	|BT| (S (NP (NN Troglitazone)) (VP (VBZ inhibits) (NP (NN tumor) (NN growth) (JJ hepatocellular) (NN carcinoma)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|8:C04 45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383|ES| 7:1 19:1 102:1 216:1 303:1 304:1 378:1 615:1 3116:1
-1 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (JJ Antidiabetic) (NNS thiazolidinediones)) (PRN (-LRB- -LRB-) (NP (NN TZD)) (-RRB- -RRB-))) (PP (FW vitro) (NP (NP (JJ antiproliferative) (NN effect) (JJ epithelial) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422|ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1
-1 	|BT| (NP (NP (NP (NP (JJ Ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (NP (NP (JJ known) (NN suppressor) (JJ cholestatic) (NN liver) (NN disease)) (JJ colorectal) (NN cancer) (NN development)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 650:C06.552 737:D04.808.105.225.272.962 879:C06.130.120.135|ES| 10:1 14:1 17:1 18:1 19:1 35:1 556:1 700:1 836:1 998:1 1275:1 2631:1 3121:1 3122:1
-1 	|BT| (S (NP (NN Valerian)) (VP (VBZ inhibits) (NP (NP (NP (NN rat) (NN hepatocarcinogenesis) (VBG activating) (NN GABA)) (PRN (-LRB- -LRB-) (NP (NN A)) (-RRB- -RRB-))) (NP (JJ receptor-mediated) (NN signaling))))) |ET| |BS|69:G02.111.087.800 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 880:D12.776.157.530.400.175.562|ES| 10:1 14:1 19:1 69:1 195:1 615:1 849:1 900:1 1958:1 3057:1 3060:1 3123:1
-1 	|BT| (NP (NP (NN Vanadium) (JJ chemopreventive) (JJ early) (NN stage) (JJ 2-AAF-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 837:D01.268.556.920 881:D02.065.064.150|ES| 19:1 849:1 900:1 1128:1 1129:1 1946:1 3124:1 3125:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (JJ possible) (NP (NP (JJ beneficial) (NN use) (NN pamidronate) (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255|ES| 10:1 14:1 19:1 303:1 304:1 441:1 546:1 843:1 984:1 1175:1 1359:1 1659:1 3126:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP find) (SBAR (S (JJ enzastaurin) (ADVP (RB potently)) (VP (VBZ reduces) (NP (NP (JJ azoxymethane-induced) (NN colon) (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (JJ PKCbetaII-mediated) (NN tumor) (NN cell) (NN proliferation) (NN beta-catenin) (NN accumulation))))))))) |ET| |BS|8:C04 16:C23.550.291.656 23:D12.776.091.249 51:C04.588.274.476.411.307.180 122:C14.280.383 132:D02.172.080 183:G04.299.233.750 866:D08.811.913.696.620.682.700.725.049|ES| 7:1 19:1 48:1 60:1 94:1 113:1 142:1 299:1 637:1 843:1 880:1 2120:1 2533:1 2855:1 3127:1 3128:1 3129:1
-1 	|BT| (S (S (S (NP (PRP We)) (VP (VBD found) (S (VP (VBG impairing) (NP (JJ autophagy) (NNS hepatocytes)))))) (VP (MD would) (VP (VB induce) (NP (JJ oxidative) (NN stress) (NN DNA) (NN damage))))) (, ,) (NP (VBD followed) (NN initiation) (NN hepatocarcinogenesis)) (, ,) (VP (MD could) (VP (VBD suppressed) (NP (NN antioxidant) (NN N-acetylcysteine))))) |ET| |BS|262:A11.436.348 390:G04.299.139.399 526:G05.355.180 700:D27.505.519.217 716:G03.495.710 791:D02.886.030.230.259|ES| 2:1 19:1 37:1 243:1 307:1 637:1 666:1 775:1 843:1 866:1 894:1 900:1 908:1 1317:1 1848:1 2521:1 2522:1 2583:1 3130:1 3131:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD demonstrated) (NP (NP (NP (JJ total) (NNP Astragalus) (NN saponin)) (PRN (-LRB- -LRB-) (NP (NNP AST)) (-RRB- -RRB-))) (NN posse) (JJ anticarcinogenic) (JJ proapoptotic) (NN property) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft)))) |ET| |BS|8:C04 41:A11 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 882:D09.408.782|ES| 7:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 265:1 333:1 772:1 841:1 843:1 1175:1 1885:1 2493:1 3048:1 3132:1 3133:1 3134:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBN shown) (SBAR (S (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (VP (VBD prevented) (SBAR (S (NP (JJ AOM-induced) (NN colon) (NN cancer)) (VP (VBD suppressed) (NP (NN Cox-2) (NN induction)))))))))) |ET| |BS|132:D02.172.080 737:D04.808.105.225.272.962|ES| 5:1 10:1 14:1 18:1 19:1 62:1 113:1 237:1 307:1 736:1 843:1 1275:1 1944:1 2630:1 2631:1 3135:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD shown) (SBAR (S (NP (NP (JJ dietary) (NN fish) (NN oil) (NN pectin)) (PRN (-LRB- -LRB-) (NP (NN FP)) (-RRB- -RRB-))) (VP (VBZ protects) (NP (NP (JJ radiation-enhanced) (NN colon) (NN cancer)) (VP (VBG upregulating) (NP (NN apoptosis) (JJ colonic) (NN mucosa))))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 46:A03.556.124.526.356 281:E02.815 302:A10.615.550 489:B01.050.150.900.493 595:G07.203.650.240 883:D10.212.302.380 884:Z01.639.760.815 885:G01.358.500.505 886:D10.627.430 887:G01.750|ES| 10:1 14:1 18:1 19:1 89:1 113:1 237:1 579:1 677:1 843:1 1863:1 2594:1 2614:1 3136:1 3137:1 3138:1 3139:1 3140:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (S (NP (NP (NN NF-kappaB) (NN suppression) (JJ novel) (NN inhibitor) (NN dimethylaminoparthenolide)) (PRN (-LRB- -LRB-) (NP (NN DMAPT)) (-RRB- -RRB-))) (VP (MD may) (VP (VB enhance) (NP (NN effect) (NN gemcitabine) (JJ pancreatic) (NN cancer)))))))) |ET| |BS|210:D12.776.260.600 259:D12.776.395.240.150.500|ES| 10:1 14:1 18:1 19:1 75:1 380:1 467:1 491:1 714:1 843:1 891:1 1690:1 2453:1 2504:1 2505:1 3141:1 3142:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (NP (JJ significant) (NN reduction) (NN number) (NN size) (JJ small) (JJ intestinal) (NN polyp) (NN APC)) (PRN (-LRB- -LRB-) (NP (NP (NN min)) (CC +) (: /) (: -)) (-RRB- -RRB-))) (NN mouse) (VBN treated) (CC either) (NP (NP (NP (NP (NN celecoxib)) (PRN (-LRB- -LRB-) (NP (JJ selective) (NN COX-2) (NN inhibitor)) (-RRB- -RRB-))) (NN erlotinib)) (PRN (-LRB- -LRB-) (NP (NP (NN Tarceva)) (, ,) (NP (NN EGFR) (NN inhibitor))) (-RRB- -RRB-)))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 52:E02 193:C23.300.825.411 349:D27.505.519.389.310.500 684:D02.065.884.247 888:D03.438.786.375|ES| 2:1 10:1 11:1 14:1 19:1 39:1 52:1 76:1 109:1 135:1 187:1 261:1 370:1 380:1 646:1 647:1 750:1 843:1 1099:1 1749:1 2142:1 2342:1 2807:1 3143:1 3144:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NN embelin)) (VP (VBZ inhibits) (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN vitro))))) (, ,) (VP (ADVP (RB effectively)) (VBZ suppresses) (NP (JJ 1,2-dimethylhydrazine) (JJ dihydrochloride-induced) (NN colon) (NN carcinogenesis) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383|ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1
-1 	|BT| (S (NP (PRP We)) (VP (VP (VBP propose) (SBAR (S (NP (JJ estrogen-mediated) (NN inhibition) (NN IL-6) (NN production) (NNS KCs)) (VP (VBZ reduces) (NP (NP (NN liver) (NN cancer) (NN risk) (NN female)) (, ,) (NP (NP (NN finding)) (VP (MD may) (VP (VBN used))))))))) (VP (VBP prevent) (NP (NN HCC) (NN male))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 61:E05.318.740.600.800 104:C04.557.470.200.025.255 201:D12.644.276.374.465.224 889:D27.505.696.399.472.277|ES| 2:1 18:1 19:1 103:1 142:1 171:1 441:1 476:1 491:1 733:1 836:1 843:1 927:1 1402:1 1404:1 2677:1 3146:1 3147:1 3148:1 3149:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ autophagy) (VBN involved) (JJ NAC1-mediated) (NN resistance) (NN cisplatin)) (, ,) (NP (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN drug) (NN treatment) (JJ ovarian) (NN cancer))))) |ET| |BS|52:E02 67:D26 151:E02.319 390:G04.299.139.399 498:D01.210.375|ES| 2:1 15:1 18:1 19:1 191:1 417:1 476:1 546:1 774:1 843:1 1094:1 1317:1 1760:1 1761:1 1762:1 1763:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD studied) (NP (NP (NN mechanism) (VBG underlying) (NN inhibition) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NN lycopene) (NN rat)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 10:1 14:1 19:1 103:1 162:1 401:1 409:1 435:1 843:1 849:1 900:1 1875:1 1952:1 2566:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP suggest) (SBAR (S (NP (NN fisetin)) (VP (MD could) (NP (JJ useful) (NN agent) (NN prevention) (NN treatment) (NN colon) (NN cancer))))))) |ET| |BS|52:E02|ES| 18:1 19:1 113:1 546:1 728:1 796:1 843:1 908:1 1036:1 1474:1 2978:1
-1 	|BT| (S (NP (NP (NNP Zerumbone)) (, ,) (NP (JJ tropical) (NN ginger) (NN sesquiterpene)) (, ,)) (VP (VBZ inhibits) (NP (NN colon) (NN lung) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 182:A04.411 762:D02.455.849.765 890:B01.650.940.800.575.100.975.900.444|ES| 2:1 19:1 52:1 113:1 207:1 328:1 615:1 2687:1 3150:1 3151:1 3152:1
1 	|BT| (S (NP (NN Protein) (NN kinase) (NN D1)) (VP (VBZ attenuates) (NP (NP (NN tumorigenesis) (NN colon) (NN cancer)) (VP (VBG modulating) (NP (NN beta-catenin/T) (NN cell) (NN factor) (NN activity)))))) |ET| |BS|23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 68:A11.118.637.555.567.569 1063:D08.811.913.696.620.682|ES| 18:1 19:1 78:1 94:1 113:1 185:1 399:1 470:1 744:1 2423:1 2435:1 2911:1 3724:1
1 	|BT| (NP (NP (NN PURPOSE) (: :)) (NP (NP (NP (NP (JJ Fatty) (NN acid) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN FAS)) (-RRB- -RRB-))) (NP (JJ overexpressed) (NN lung) (NN cancer))) (, ,) (VP (VBD investigated) (NP (JJ potential) (NN use) (NN FAS) (NN inhibitor) (NN chemoprevention) (NN lung) (NN cancer))))) |ET| |BS|253:E02.319.162 921:D08.811.682.664.500.772 922:D10.251|ES| 2:1 10:1 14:1 18:1 19:1 25:1 66:1 104:1 328:1 380:1 403:1 687:1 827:1 870:1 1275:1 1659:1 3725:1 3726:1
1 	|BT| (NP (NP (NP (NP (NN PURPOSE) (: :)) (NN Obesity) (JJ related) (JJ metabolic) (NN abnormality)) (, ,) (PP (VBG including) (NP (NP (NN insulin) (NN resistance)) (VP (NN activation) (NP (NP (NP (JJ insulin-like) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN IGF)) (-RRB- -RRB-))) (: /) (NP (NP (NP (NN IGF-I) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IGF-IR)) (-RRB- -RRB-))) (NN axis) (, ,) (NN risk) (NN factor) (NN colon) (NN cancer)))))))) |ET| |BS|254:C16.131 409:E05.318.740.600.800.725 518:D08.811.913.696.620.682.725.400.185 564:C18.654.726.500 579:A02.835.232.834.151.383 581:D12.644.276.937 678:C18.452.394.968.500 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 10:1 14:1 18:1 19:1 102:1 104:1 113:1 171:1 185:1 186:1 225:1 419:1 561:1 687:1 1027:1 1094:1 2006:1 2089:1 2093:1 2364:1 3727:1 3728:1 3729:1 3730:1
1 	|BT| (S (NP (NP (NN PURPOSE) (: :)) (NP (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription-3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (JJ downstream) (NN growth) (NN factor) (NN cytokine) (NN receptor))) (, ,)) (VP (VBZ regulates) (NP (NP (JJ key) (JJ oncogenic) (NN pathway) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))))) |ET| |BS|82:D12.644.360.024.342.300 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 279:D27.888.569.100 897:Z01.252.245.500.375 1066:D12.776.543.750.705.852|ES| 2:1 10:1 14:1 18:1 19:1 94:1 102:1 104:1 159:1 185:1 186:1 251:1 328:1 329:1 383:1 560:1 603:1 687:1 694:1 860:1 861:1 953:1 2676:1 2960:1 3731:1
1 	|BT| (NP (NP (NP (JJ Quantitative) (NN analysis) (JJ basic) (NN fibroblast) (NN growth) (NN factor) (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (NP (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 1067:D12.644.276.624.120|ES| 17:1 18:1 19:1 36:1 102:1 185:1 661:1 1251:1 2213:1 3092:1 3732:1 3733:1
1 	|BT| (NP (NP (NP (VBN Reduced) (NN expression) (NN cyclooxygenase) (CD 2) (NN protein) (JJ hereditary) (JJ nonpolyposis) (JJ colorectal) (NN cancer)) (JJ relative) (JJ sporadic) (NN cancer))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 524:C04.588.274.476.411.307.190|ES| 4:1 17:1 18:1 19:1 115:1 148:1 725:1 1531:1 1845:1 1846:1 3180:1 3734:1
1 	|BT| (S (NP (NN Regrowth) (JJ 5-fluorouracil-treated) (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBD prevented) (NP (NP (NN combination) (NN interferon) (NN gamma)) (, ,) (NP (NN indomethacin)) (, ,) (NP (NN phenylbutyrate))))) |ET| |BS|41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 795:D03.438.473.420 1033:D12.644.276.374.440.893 1068:D02.241.223.651|ES| 2:1 18:1 19:1 36:1 94:1 113:1 530:1 1944:1 2305:1 2389:1 2792:1 3735:1 3736:1 3737:1
1 	|BT| (NP (NP (NNS RESULTS) (: :)) (NP (NP (NN 5-LOX) (VBN overexpressed) (JJ adenomatous) (NN polyp) (NN cancer)) (NP (VBN compared) (JJ normal) (JJ colonic) (NN mucosa)))) |ET| |BS|46:A03.556.124.526.356 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215|ES| 18:1 19:1 25:1 50:1 57:1 104:1 118:1 579:1 647:1 677:1 710:1 3390:1
1 	|BT| (S (NP (NNS RESULTS)) (: :) (S (NP (NN Microarray) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (NN osteopontin)) (, ,) (NP (NN marker) (NN colon) (NN cancer) (NN progression)) (, ,)) (VP (VBD down-regulated) (NP (NP (NP (NN polyp) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Delta14)) (: /) (CC +) (-RRB- -RRB-))) (NN mouse) (VBN given) (NN parecoxib)) (NP (VBN compared) (NN control)))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 142:I01.880.604 158:D23.101 350:D12.644.276.374.625 351:A17.360 444:C23.300.825 718:E05.588.570|ES| 2:1 10:1 14:1 18:1 19:1 29:1 48:1 50:1 52:1 104:1 113:1 275:1 280:1 281:1 289:1 534:1 647:1 661:1 710:1 1160:1 1283:1 3738:1 3739:1
1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (NP (NN Nestin) (NN expression)) (ADVP (RB significantly)) (VP (VBD associated) (NP (NP (JJ poor) (NN survival) (NN patient) (JJ triple-negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-)))))) |ET| |BS|50:M01.643 96:I03.784 159:I01.880.735.634 160:C04.588.180.788 1047:D05.750.078.593.540|ES| 10:1 14:1 18:1 19:1 23:1 26:1 104:1 115:1 120:1 124:1 169:1 274:1 311:1 315:1 545:1 581:1 710:1 3650:1
1 	|BT| (S (NP (NN Resveratrol)) (VP (VBZ induces) (NP (NP (NN chemosensitization) (NN 5-fluorouracil) (NN up-regulation) (JJ intercellular) (NN junction)) (, ,) (NP (JJ Epithelial-to-mesenchymal) (NN transition) (NN apoptosis) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 142:I01.880.604 495:G04.299.335.500 560:D03.383.742.698.875.404 1054:A11.284.149.165.420|ES| 2:1 17:1 18:1 19:1 89:1 214:1 552:1 896:1 2307:1 2946:1 3679:1 3680:1 3740:1 3741:1
1 	|BT| (S (S (NP (NP (NN RNA) (NN interference) (JJ knockdown) (NN DRD2) (NN inhibition) (JJ pharmacologic) (NN antagonist)) (PRN (-LRB- -LRB-) (NP (NN pimozide) (NN haloperidol)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NN proliferation) (JJ pancreatic) (NN cancer) (NN cell)))) (, ,) (VP (VBD induced) (NP (NP (JJ endoplasmic) (NN reticulum) (NN stress) (NN apoptosis)) (, ,) (NP (VBN reduced) (NN cell) (NN migration))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 156:G05.355.315.203.374.790 183:G04.299.233.750 362:D12.776.543.750.069.300.400.500 681:G04.299.283 1059:H01.158.703 1069:D02.522.352.506 1070:D03.438.103.732 1071:G04.434|ES| 2:1 10:1 14:1 18:1 19:1 89:1 94:1 103:1 299:1 412:1 452:1 464:1 467:1 514:1 515:1 516:1 1210:1 1271:1 2522:1 3742:1 3743:1 3744:1 3745:1 3746:1
1 	|BT| (S (NP (NN Role) (NN microRNA-155) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ choline-deficient) (NN amino) (JJ acid-defined) (NN diet) (NN C57BL/6) (NN mouse)))) |ET| |BS|15:F01.829.316.616 184:D13.150.650.319 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 19:1 52:1 412:1 900:1 1128:1 1129:1 1957:1 2187:1 2188:1 2189:1 2190:1 2191:1 2192:1
1 	|BT| (NP (NP (NN Role) (JJ transcriptional) (JJ posttranscriptional) (NN regulation) (NN methionine) (NNS adenosyltransferases) (NN liver) (NN cancer) (NN progression))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 142:I01.880.604 209:G02.111.087.847 574:D08.811.913.225.650|ES| 18:1 19:1 48:1 438:1 559:1 836:1 1493:1 2050:1 2187:1 3747:1
1 	|BT| (S (NP (NN Roxithromycin)) (VP (VBZ inhibits) (S (NP (NP (JJ constitutive) (NN activation) (JJ nuclear) (NN factor)) (-LRB- -LCB-) (NN kappa) (-RRB- -RCB-) (NN B)) (VP (VBG diminishing) (NP (JJ oxidative) (NN stress) (NN rat) (NN model) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 104:C04.557.470.200.025.255 122:C14.280.383 210:D12.776.260.600 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 843:D02.540.576.500.992.630|ES| 19:1 72:1 185:1 225:1 303:1 304:1 604:1 615:1 763:1 849:1 1256:1 2522:1 2583:1 3748:1 3749:1 3750:1 3751:1 3752:1
1 	|BT| (NP (NP (JJ Seleno-cyclodextrin) (NNS sensitises) (JJ human) (NN breast) (NN cancer) (NN cell) (JJ TRAIL-induced) (NN apoptosis) (NN DR5) (NN induction) (NN NF-kappaB) (NN suppression))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 210:D12.776.260.600 1072:D04.345.103|ES| 18:1 19:1 23:1 36:1 89:1 94:1 714:1 736:1 2453:1 3682:1 3753:1 3754:1 3755:1
1 	|BT| (S (NP (NN Selenoprotein) (NN deficiency) (JJ high) (NN level) (NN selenium) (NN compound)) (ADVP (RB effectively)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (JJ transgenic) (NN mouse)))) |ET| |BS|87:C18.654.521 99:B01.050.050.136.500 122:C14.280.383 1073:D12.776.864 1074:D01.810|ES| 19:1 52:1 178:1 249:1 253:1 285:1 900:1 1370:1 2433:1 2977:1 3284:1 3756:1
1 	|BT| (S (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (VP (VBZ mediates) (NP (NN pathogenesis) (NN colon) (NN cancer) (NN substrate) (NN PTK6)))) |ET| |BS|209:G02.111.087.847 250:E07.305.812|ES| 10:1 14:1 18:1 19:1 113:1 251:1 487:1 501:1 755:1 860:1 861:1 862:1 1041:1 2960:1 3757:1
1 	|BT| (S (NP (NN Simvastatin)) (VP (VP (VBZ induces) (NP (NN apoptosis) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft))) (, ,) (VP (VBZ attenuates) (NP (JJ colitis-associated) (NN colon) (NN cancer) (NN mouse))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900|ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1
1 	|BT| (S (NP (NP (NN Sodium) (NN butyrate)) (PRN (-LRB- -LRB-) (NP (NN NaB)) (-RRB- -RRB-))) (VP (VP (VBZ inhibits) (NP (NN proliferation))) (, ,) (VP (VBZ stimulates) (NP (NN apoptosis))) (, ,) (VP (VBZ promotes) (NP (NN differentiation) (JJ human) (NN colon) (NN cancer) (NN cell)) (PP (IN along) (NP (JJ absorptive) (NN phenotype)))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 122:C14.280.383 1075:D02.241.081.114.750|ES| 2:1 10:1 14:1 18:1 19:1 36:1 89:1 94:1 113:1 215:1 236:1 298:1 299:1 615:1 2666:1 2962:1 3758:1 3759:1 3760:1 3761:1
1 	|BT| (S (NP (NNP Sorafenib)) (VP (VBZ sensitizes) (NP (JJ hepatocellular) (ADJP (NN carcinoma) (NN cell) (JJ physiological)) (JJ apoptotic) (NN stimulus)))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255 230:G04|ES| 19:1 94:1 303:1 304:1 2062:1 2223:1 2730:1 3210:1 3762:1
1 	|BT| (NP (NP (NP (NN SRJ09)) (PRN (-LRB- -LRB-) (NP (CD 3,19) (: -) (-LRB- -LRB-) (NN 2-bromobenzylidene) (-RRB- -RRB-) (NN andrographolide)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ semisynthetic) (NN andrographolide)) (PRN (-LRB- -LRB-) (NP (NN AGP)) (-RRB- -RRB-))) (NP (NN derivative)) (, ,) (VP (VBN shown) (VP (VBP induce) (NP (NN G1) (NN cell) (NN cycle) (NN arrest)) (NP (ADVP (RB eventually)) (NP (NN apoptosis) (NN breast) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|10:A01.236 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 94:A11.251.210 1076:G04.299.134.109.249|ES| 2:1 10:1 14:1 18:1 19:1 23:1 89:1 94:1 113:1 237:1 243:1 264:1 601:1 602:1 670:1 2813:1 3763:1 3764:1 3765:1 3766:1 3767:1 3768:1 3769:1
1 	|BT| (NP (NP (NN Sulindac) (NN reversal) (JJ 15-PGDH-mediated) (NN resistance) (NN colon) (NN tumor) (NN chemoprevention) (NNS NSAIDs))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500|ES| 7:1 19:1 113:1 870:1 1094:1 2965:1 2966:1 3770:1 3771:1
1 	|BT| (NP (NP (NP (JJ Suppressive) (NN effect)) (NP (ADJP (RB enzymatically) (VBN modified)) (NN isoquercitrin) (JJ phenobarbital-induced) (NN liver) (NN tumor) (NN promotion) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650|ES| 7:1 19:1 75:1 836:1 849:1 2335:1 2337:1 3772:1 3773:1 3774:1 3775:1
1 	|BT| (S (NP (JJ Suppressive) (NN effect) (NN liver) (JJ tumor-promoting) (NN activity) (NN rat)) (VP (VBN subjected) (NP (JJ combined) (NN administration) (JJ phenobarbital) (NN piperonyl) (NN butoxide)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 756:D03.383.742.698.253.650 1077:D03.383.246.118.600|ES| 19:1 75:1 164:1 399:1 836:1 849:1 2575:1 2685:1 3267:1 3772:1 3776:1 3777:1 3778:1
1 	|BT| (S (NP (NN Survivin) (NN overexpression)) (VP (VBN associated) (NP (NP (JJ poor) (NN prognosis) (JJ human) (JJ gastric) (NN cancer)) (, ,) (NP (NN target) (JJ gastric) (NN cancer) (NN therapy))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 159:I01.880.735.634 163:E01.789|ES| 2:1 18:1 19:1 36:1 86:1 130:1 152:1 160:1 169:1 544:1 545:1 3779:1
1 	|BT| (NP (NP (NP (NN Susceptibility) (NN aflatoxin) (JJ B1-related) (JJ primary) (JJ hepatocellular) (NN carcinoma) (NN mouse)) (ADJP (JJ human)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 401:C23.550.291.687 1078:D03.383.663.283.119.075|ES| 19:1 36:1 52:1 303:1 304:1 344:1 2214:1 3780:1 3781:1
1 	|BT| (NP (NP (JJ Synergistic) (JJ chemopreventive) (NN effect) (NN nobiletin) (NN atorvastatin) (NN colon) (NN carcinogenesis))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 624:D27.505.696.706.018|ES| 19:1 75:1 113:1 207:1 1946:1 3782:1 3783:1 3784:1
1 	|BT| (SINV (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (VP (VBG finding) (VP (VBP demonstrate) (SBAR (S (NP (NN pectolinarigenin)) (VP (MD may) (NP (NP (NN candidate) (NN osteosarcoma) (NN intervention)) (VP (VBN linked) (NP (NP (NN STAT3)) (NN signaling) (JJ inhibitory) (NN activity))))))))))) |ET| |BS|69:G02.111.087.800 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650|ES| 2:1 19:1 106:1 195:1 251:1 399:1 491:1 502:1 927:1 1243:1 1363:1 1537:1 1538:1 1562:1 2429:1 2785:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VBP provide) (NP (JJ direct) (NN evidence) (JJ decorin-mediated) (NN inhibition) (JJ colorectal) (NN cancer) (NN growth) (NN migration) (NN interaction) (NN stabilization) (NN E-cadherin))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625|ES| 2:1 17:1 18:1 19:1 38:1 101:1 102:1 103:1 514:1 618:1 711:1 1537:1 1538:1 1891:1 2267:1 3785:1 3786:1
1 	|BT| (S (NP (NN Tandutinib)) (VP (VBZ inhibits) (S (NP (NN Akt/mTOR) (NN signaling) (NN pathway)) (VP (VBP inhibit) (NP (NN colon) (NN cancer) (NN growth)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 378:D08.811.913.696.620.682.700.755|ES| 18:1 19:1 102:1 113:1 195:1 383:1 615:1 1370:1 2819:1 3787:1
1 	|BT| (NP (NP (NP (NN Targeting) (NN cyclooxygenase-2) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN prevention) (NN treatment)) (JJ intestinal) (NP (NN cancer)))) |ET| |BS|24:D08.811.600.720.750 52:E02 64:D08.811.913.696.620.682.725.400.009.300 101:C04.588.274.476.411|ES| 18:1 19:1 61:1 102:1 109:1 184:1 185:1 186:1 546:1 1474:1 2100:1
1 	|BT| (FRAG (NP (NP (DT The) (NN aim) (NN work)) (VBP characterize) (NP (NP (NN effect) (NN CAPE) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (VBN involved) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NN metabolism) (NN initiation) (NN stage) (NN chemical) (NN hepatocarcinogenesis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 445:I03.946 554:D02.654.442.200 898:G03.495 1079:D08.244.453|ES| 2:1 10:1 14:1 19:1 75:1 637:1 691:1 774:1 900:1 1129:1 1546:1 1567:1 1875:1 1952:1 2124:1 2252:1 2332:1 2549:1 3163:1 3788:1 3789:1
1 	|BT| (FRAG (NP (NP (DT The) (JJ angiogenic) (NN inducer) (NN CYR61)) (PP (RB differentially) (NP (NP (NP (JJ overexpressed) (NN breast) (NN cancer) (NN cell)) (VP (VBG exhibiting) (NP (NP (JJ high) (NN level) (NN Heregulin)) (PRN (-LRB- -LRB-) (NP (NN HRG)) (-RRB- -RRB-))))) (, ,) (NP (NN growth) (NN factor)) (NP (ADVP (RB closely)) (NP (VBN associated) (JJ metastatic) (NN breast) (NN cancer) (NN phenotype))))))) |ET| |BS|10:A01.236 41:A11 80:G05.695 113:C04.697.650 175:J01.897.280.500.269 1080:D12.644.276.860.550.750 1081:D12.644.276.860.550|ES| 2:1 10:1 14:1 18:1 19:1 23:1 25:1 94:1 102:1 169:1 178:1 185:1 236:1 249:1 337:1 691:1 855:1 1139:1 3790:1 3791:1 3792:1 3793:1 3794:1 3795:1
1 	|BT| (S (NP (DT The) (JJ anti-tumor) (NN effect) (NN thymoquinone)) (ADVP (RB also)) (VP (VP (VBD investigated) (NP (NN tumor) (NN xenograft) (NN mouse) (NN model) (NN colon))) (, ,) (NP (NN prostate) (, ,) (JJ pancreatic) (NN lung) (NN cancer)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 34:A05.360.444.575 46:A03.556.124.526.356 92:E04.936.764 93:A01.941.875 608:A03.734|ES| 2:1 5:1 7:1 18:1 19:1 52:1 72:1 75:1 77:1 113:1 265:1 328:1 403:1 467:1 691:1 3677:1 3796:1
1 	|BT| (S (NP (DT The) (NN blockade) (NN 5-LOX)) (VP (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN proliferation)) (ADVP (FW vitro) (FW vivo))) (SBAR (S (VP (MD may) (VP (VB prove) (NP (JJ beneficial) (JJ chemopreventive) (NN therapy) (NN colon) (NN cancer)))))))) |ET| |BS|52:E02 122:C14.280.383 183:G04.299.233.750 548:D08.811.682.664.500.848|ES| 18:1 19:1 94:1 113:1 130:1 216:1 299:1 378:1 491:1 615:1 691:1 984:1 1946:1 2669:1 3390:1 3797:1
1 	|BT| (NP (NP (NP (DT The) (VBN cooked) (NN meat)) (VBN derived) (JJ genotoxic) (NN carcinogen) (JJ 2-amino-3-methylimidazo) (PRN (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-)) (NN pyridine) (JJ potent) (JJ hormone-like) (NN activity)) (: :) (NP (NP (JJ mechanistic) (NN support) (NN role)) (NN breast) (NN cancer))) |ET| |BS|15:F01.829.316.616 161:D06.472 279:D27.888.569.100 744:D03.383.725 1082:J01.576.423.200.200 1083:G07.203.300.600|ES| 18:1 19:1 22:1 23:1 31:1 104:1 399:1 691:1 1364:1 1373:1 1378:1 1721:1 1890:1 2125:1 2639:1 2640:1 3329:1 3581:1 3798:1 3799:1 3800:1
1 	|BT| (FRAG (NP (NP (DT The) (NN copper) (NN chelator) (NN trientine) (JJ antiangiogenic) (NN effect)) (NP (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (ADVP (RB possibly)) (NN inhibition) (NN interleukin-8) (NN production)))) |ET| |BS|12:Z01.542.049 43:F01.145.544 104:C04.557.470.200.025.255 1084:D12.644.276.374.200.120.800 1085:D02.092.782.258.368.880 1086:D27.505.696.377.077.099 1087:D27.505.519.914.500 1088:D01.268.556.195|ES| 2:1 19:1 75:1 103:1 303:1 304:1 691:1 1548:1 2677:1 3801:1 3802:1 3803:1 3804:1 3805:1
1 	|BT| (NP (NNS defensins) (NP (NP (NN matrilysin)) (, ,) (S (ADVP (RB highly)) (VP (VBN overexpressed) (NP (NN colon) (NN cancer)))))) |ET| |BS|937:D08.811.277.656.300.480.525.700.250 1089:D12.644.050.200|ES| 2:1 18:1 19:1 25:1 113:1 626:1 3289:1 3806:1
1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
1 	|BT| (S (NP (DT The) (NN effect) (NN honokiol) (NN invasion) (NN migration) (NN breast) (NN cancer) (NN cell)) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (NNP Matrigel) (NN invasion)) (, ,) (NP (NN scratch-migration)) (, ,) (NP (NN spheroid-migration)) (, ,) (NP (NP (JJ electric) (JJ cell-substrate) (NN impedance)) (VP (VBG sensing) (NP (-LRB- -LRB-) (NP (NN ECIS) (-RRB- -RRB-) (: -)) (VBN based) (NN migration) (NN assay))))))))) |ET| |BS|225:E05.337 333:D01.045 681:G04.299.283 1090:G01.358.500.249.277.350 1091:E01.370.225.500.335 1092:G01.358.500.249 1093:F02.830.816|ES| 2:1 10:1 14:1 18:1 19:1 23:1 75:1 94:1 310:1 350:1 514:1 620:1 691:1 780:1 2895:1 3574:1 3807:1 3808:1 3809:1 3810:1 3811:1 3812:1 3813:1 3814:1
1 	|BT| (S (NP (DT The) (JJ monoclonal) (NN antibody) (NN CH12)) (VP (VBZ augments) (NP (NP (JJ 5-fluorouracil-induced) (NN growth) (NN suppression) (JJ hepatocellular) (NN carcinoma) (NN xenograft)) (VP (VBG expressing) (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN variant) (CD III)))))) |ET| |BS|45:G07.700.320.249 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 1094:D12.776.124.125.900 1095:A10.272.497|ES| 19:1 102:1 184:1 185:1 186:1 265:1 303:1 304:1 691:1 810:1 990:1 1365:1 2281:1 2453:1 2611:1 3815:1 3816:1 3817:1
1 	|BT| (S (NP (NP (DT The) (NP (JJ murine) (JJ non-pancreatic) (JJ secretory) (NN phospholipase) (NN A)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN sPLA) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (-RRB- -RRB-))) (VP (VBN proposed) (NP (NP (NN tumor) (NN modifier) (JJ multiple) (JJ intestinal) (NN neoplasia)) (PRN (-LRB- -LRB-) (NP (NN Min)) (-RRB- -RRB-))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 192:D08.811.277.352.100.680.750.937.750 608:A03.734|ES| 7:1 10:1 14:1 19:1 30:1 69:1 109:1 148:1 627:1 640:1 643:1 644:1 649:1 650:1 691:1 2129:1 3818:1 3819:1
1 	|BT| (S (NP (DT The) (NN neurotensin) (NN receptor-1)) (VP (VBZ promotes) (NP (NN tumor) (NN development) (JJ sporadic) (JJ inflammation-associated) (NN mouse) (NN model) (NN colon) (NN cancer)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 53:C06.405.205.265 525:C23.550.470 1048:D12.776.543.750.100.550|ES| 7:1 18:1 19:1 35:1 52:1 72:1 113:1 298:1 691:1 725:1 1849:1 3657:1 3820:1
1 	|BT| (S (NP (NP (DT The) (NN observation) (NN TKO) (NN mouse) (JJ resistant) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN dioxin) (NN liver)))) (VP (VBZ suggests) (SBAR (S (NP (JJ inflammatory) (NN cytokine) (NN play) (JJ important) (NN step) (NN dioxin)) (VP (VBD mediated) (NP (NN liver) (NN tumor) (NN promotion) (NN mouse))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 79:I03.450.642.693 242:A03.620 429:N04.761.559.590.900 430:E05.581.249 515:C04.588.274.623 752:D12.644.276.374 1096:D03.383.231.900 1097:D03.383.231|ES| 7:1 19:1 52:1 75:1 238:1 331:1 427:1 437:1 691:1 836:1 881:1 902:1 1477:1 2087:1 2337:1 2430:1 2676:1 3821:1 3822:1
1 	|BT| (NP (NP (NP (DT The) (NN potency) (JJ nifuroxazide) (NN breast) (NN cancer)) (VP (VBN assessed) (ADVP (FW vitro) (FW vivo))))) |ET| |BS||ES| 18:1 19:1 23:1 216:1 378:1 691:1 2796:1 2820:1 3823:1
1 	|BT| (NP (NP (NP (DT The) (JJ potential) (NN utility) (NN acetyltanshinone) (NN IIA) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer)) (: :) (NP (NP (NN Induction) (NN cancer) (NN cell) (NN death)) (VP (VBG targeting) (NP (JJ apoptotic) (JJ metabolic) (NN signaling) (NN pathway)))))) |ET| |BS|33:C04.697.098 39:G04.299.139.160 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 126:G02.111.087.800 134:G04.299.139 605:G03.495.553|ES| 18:1 19:1 23:1 94:1 104:1 195:1 383:1 411:1 546:1 616:1 691:1 827:1 2006:1 2020:1 2194:1 2195:1 2221:1 2222:1 2223:1
1 	|BT| (S (NP (DT The) (JJ present) (NN work)) (VP (VBN conducted) (VP (VBP examine) (S (NP (NP (NN effect) (NN thymosin) (NN beta-4)) (PRN (-LRB- -LRB-) (NP (NN Tbeta4)) (-RRB- -RRB-))) (NP (NP (NN upregulation) (NN apoptosis) (NN SW480) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN induced) (NN T) (NN cell) (JJ various) (JJ chemotherapeutic) (NN agent)) (VP (VBD reduced) (NP (NP (NP (NN susceptibility) (NN cytotoxicity) (JJ anti-Fas) (NN IgM)) (PRN (-LRB- -LRB-) (NP (NN CH-11)) (-RRB- -RRB-))) (NP (JJ Tbeta4-overexpressing) (NN cell))) (ADVP (RB previously)) (VP (VBD reported) (NP (NN u))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 68:A11.118.637.555.567.569 249:G05.355.315.800 339:G02.111.087.880 401:C23.550.291.687 445:I03.946 660:D27.505.954.248 876:F01.145 946:D27.888.569.213|ES| 10:1 14:1 18:1 19:1 75:1 89:1 94:1 113:1 412:1 452:1 691:1 728:1 960:1 993:1 1096:1 1126:1 1307:1 1353:1 1527:1 1546:1 1762:1 2243:1 3096:1 3100:1 3317:1 3824:1 3825:1 3826:1 3827:1 3828:1 3829:1 3830:1 3831:1
1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP demonstrate) (NP (NP (JJ growth-promoting) (NN property) (NN periostin)) (, ,) (NP (NP (JJ possible) (NN role)) (VP (VBG targeting) (NP (NN protein) (JJ therapeutic) (NN option) (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 15:F01.829.316.616 45:G07.700.320.249 52:E02 112:D12.776.097.820|ES| 2:1 4:1 17:1 18:1 19:1 31:1 101:1 502:1 541:1 616:1 691:1 841:1 1359:1 3512:1 3832:1 3833:1
1 	|BT| (S (NP (DT The) (NN result)) (VP (VBD demonstrated) (SBAR (S (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (NN Wnt2) (NN expression) (JJ cytoplasmic/nuclear) (NN beta-catenin) (NN accumulation)) (VP (VBD appeared) (NP (JJ gastric) (NN cancer) (JJ irrespective) (JJ morphological) (NN phenotype)))) (, ,) (FRAG (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (JJ over-expressed) (NN Wnt) (JJ nuclear) (NN translocalisation) (NN beta-catenin)) (VBD found) (NP (NP (ADJP (QP (CD 68) (CD 58)) (NN %)) (NN i-GCs) (CD 47) (ADJP (CD 47) (NN %)) (NN d-GCs)) (NP (ADJP (RB closely) (JJ related)) (NN pattern)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))) (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (NP (NN co-existence) (NN Wnt2) (NN up-regulation/beta-catenin) (JJ nuclear) (NN translocalisation)) (ADJP (NP (NP (ADJP (RB positively) (VBN associated)) (NN lymph) (NN node) (NN metastasis)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.05)))) (-RRB- -RRB-))) (ADJP (RB well) (JJ T-stage))))))))) |ET| |BS|23:D12.776.091.249 80:G05.695 113:C04.697.650 142:I01.880.604 703:A10.549.400 967:D01.248.497.158.490 1042:Z01.107.757.284 1098:A11.284.430.214|ES| 2:1 10:1 14:1 18:1 19:1 37:1 60:1 86:1 98:1 101:1 115:1 148:1 169:1 236:1 260:1 311:1 312:1 315:1 369:1 419:1 691:1 787:1 806:1 855:1 862:1 877:1 1175:1 1256:1 2120:1 2536:1 2537:1 3834:1 3835:1 3836:1 3837:1 3838:1 3839:1 3840:1 3841:1 3842:1 3843:1 3844:1 3845:1 3846:1 3847:1 3848:1 3849:1 3850:1
1 	|BT| (S (NP (DT The) (NN result) (NN study)) (VP (VBP suggest) (SBAR (S (S (NP (NP (NN E1AF)) (, ,) (NP (NP (NN expression)) (ADVP (RB closely)))) (VP (VBD correlated) (NP (NN expression) (NN matrilysin)))) (, ,) (VP (VBP play) (NP (JJ key) (NN role) (NN progression) (JJ gastric) (NN cancer))))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 79:I03.450.642.693 937:D08.811.277.656.300.480.525.700.250|ES| 2:1 18:1 19:1 31:1 48:1 86:1 101:1 115:1 131:1 159:1 238:1 446:1 691:1 796:1 855:1 3289:1 3484:1
1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP provide) (SBAR (S (NP (NN evidence) (JJ major) (NN role) (NN beta-catenin/Apc) (NN pathway) (NN development) (JJ heterocyclic) (JJ amine-induced) (NN colon) (NN tumor)) (VP (VBP give) (NP (NN weight) (NN view) (NN regulation) (NN beta-catenin) (JJ critical) (NN tumor) (JJ suppressive) (NN effect) (NN Apc) (NN colon) (NN carcinogenesis))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 15:F01.829.316.616 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 142:I01.880.604 653:C23.888.144 856:D02.092|ES| 7:1 19:1 31:1 35:1 38:1 60:1 75:1 101:1 113:1 207:1 280:1 383:1 438:1 462:1 691:1 711:1 825:1 1626:1 1974:1 2399:1 3054:1 3055:1 3851:1 3852:1
1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN MTHFR) (NN genotype) (JJ relevant) (JJ independent) (NN factor) (NN patient) (NN outcome) (JJ 5FU-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 333:D01.045 396:G05.380 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 17:1 18:1 19:1 101:1 120:1 185:1 546:1 547:1 691:1 796:1 865:1 883:1 997:1 1329:1 2231:1 2232:1
1 	|BT| (S (NP (DT The) (NNP Ron) (NN receptor) (NN tyrosine) (NN kinase)) (VP (VBD overexpressed) (NP (ADJP (RB approximately) (JJ half)) (JJ human) (NN colon) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 25:1 36:1 113:1 186:1 470:1 691:1 1843:1 2341:1 3853:1 3854:1
1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP indicate) (SBAR (S (NP (NN Wnt/beta-catenin) (NN signalling) (NN pathway)) (VP (VBD activated) (NP (JJ gastric) (NN cancer)))))) (, ,) (VP (MD may) (VP (VB play) (NP (NP (JJ pivotal) (NN role)) (NP (CC either) (NP (JJ gastric) (NN cancer) (NN formation) (NN tumour) (NN invasion) (NN dissemination)))))))) |ET| |BS|8:C04 15:F01.829.316.616 20:G03.495 23:D12.776.091.249 69:G02.111.087.800 79:I03.450.642.693|ES| 2:1 18:1 19:1 31:1 39:1 43:1 86:1 163:1 238:1 302:1 383:1 491:1 620:1 792:1 793:1 795:1 1011:1 1479:1 2437:1 3248:1
1 	|BT| (NP (NP (DT These) (S (VP (VBG finding) (VP (VB provide) (NP (NP (JJ important) (NN information) (NN interaction)) (PP (IN among) (NP (NP (VBG transforming) (NN growth) (NN factor) (NN beta)) (, ,) (NP (NN BMP)) (, ,) (NP (NN Wnt) (NN signaling) (NN pathway) (NN progression) (NN CRC)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 147:G02.149.115.800.925 503:D12.644.276.374.687 1099:D12.644.276.954.200|ES| 2:1 19:1 48:1 102:1 185:1 195:1 245:1 383:1 618:1 711:1 792:1 877:1 902:1 927:1 1372:1 1772:1 1972:1 2338:1 3855:1
1 	|BT| (SINV (NP (DT These)) (VBG finding) (ADVP (RB strongly)) (VBP suggest) (NP (NP (NP (NN estrogen) (NN play) (JJ critical) (NN role)) (NP (JJ female) (NN hepatocarcinogenesis))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 642:M01.975 889:D27.505.696.399.472.277|ES| 19:1 31:1 238:1 635:1 792:1 796:1 825:1 900:1 927:1 1404:1 3168:1
1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP suggest) (S (ADVP (RB aberrantly)) (VP (VBN expressed) (SBAR (S (NP (NN CARM1) (NN tumor) (JJ marker-positive) (NN cell)) (VP (VBZ promotes) (NP (NN tumorigenesis) (JJ early) (NN stage) (NN hepatocarcinogenesis)))))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 41:A11 376:D23.101.140|ES| 6:1 7:1 19:1 78:1 94:1 298:1 792:1 796:1 900:1 927:1 1128:1 1129:1 2657:1 3856:1 3857:1
1 	|BT| (S (NP (DT These) (NN observation)) (VP (VBP suggest) (SBAR (S (NP (JJR safer) (JJ efficacious) (NN sulindac) (NN derivative)) (VP (VBD developed) (NP (NP (JJ colorectal) (NN cancer) (NN chemoprevention)) (VP (VBG targeting) (NP (NN PDE5)) (VP (ADVP (RB possibly)) (NP (JJ cGMP-degrading) (NNS isozymes)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 251:D02.455.426.559.847.486.875 253:E02.319.162 429:N04.761.559.590.900 430:E05.581.249 993:D08.811.348 1100:D03.438.759.646.454.160 1101:N06.850.135.060.075|ES| 17:1 18:1 19:1 190:1 616:1 792:1 796:1 869:1 870:1 1165:1 1477:1 1548:1 2813:1 3858:1 3859:1 3860:1 3861:1
1 	|BT| (S (NP (NNS Thiazolidinediones)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (NN hepatitis) (NN B) (JJ virus-transgenic) (NN mouse) (NN peroxisome) (JJ proliferator-activated) (NN receptor) (JJ gamma-independent) (NN regulation) (NN nucleophosmin)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 99:B01.050.050.136.500 122:C14.280.383 142:I01.880.604 719:D12.776.826.239.588 862:D02.886.675.933 863:B04.280.375.650.425|ES| 19:1 52:1 186:1 438:1 763:1 900:1 1370:1 1801:1 1887:1 2048:1 3069:1 3070:1 3071:1 3072:1
1 	|BT| (S (NP (DT This)) (VP (VBZ indicates) (SBAR (S (S (NP (JJ low) (NN level) (JJ active) (NN Caspase-3)) (VP (MD may) (VP (VB represent) (S (NP (NP (JJ new) (NN predictor) (NN CT) (NN responsiveness)) (, ,) (NP (NN inhibition) (NN Caspase-3)) (, ,)) (VP (VBG antagonising) (NP (JJ downstream) (NN effector) (NN Caspase-3) (NN paracrine) (NN signalling))))))) (, ,) (NP (NN COX-2)) (VP (MD may) (VP (VB improve) (NP (NP (NN patient) (NN outcome)) (VP (VBG following) (SBAR (S (NP (NNP CT)) (VP (VBD advanced) (NP (NN CRC))))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 50:M01.643 906:D08.811.277.656.262.500.126.350.300 1102:Z01.058.290.100.120 1103:G04.299.122.600|ES| 2:1 19:1 76:1 103:1 120:1 197:1 245:1 249:1 491:1 531:1 547:1 560:1 570:1 628:1 712:1 799:1 807:1 997:1 2437:1 2466:1 3190:1 3510:1 3862:1 3863:1 3864:1 3865:1 3866:1
1 	|BT| (S (NP (DT This)) (VP (VBD led) (SBAR (S (NP (NN u)) (VP (VBP investigate) (SBAR (S (NP (NP (JJ antitumor) (NN growth)) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin) (JJ immunocompetent) (NN xenograft) (NN model) (NN mouse) (JJ metastatic) (JJ mammary) (NN cancer) (NN p53) (NN mutation))) (VP (VBZ induces) (NP (NP (JJ metastatic) (NN spectrum)) (NP (JJ similar) (VBN seen) (JJ human) (NN breast) (NN cancer))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460|ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1
1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (JJ NAC1-mediated) (NN autophagy)) (VP (MD may) (VP (VBN exploited) (NP (JJ new) (NN target) (VBG enhancing) (NN efficacy) (NN cisplatin) (JJ ovarian) (NN cancer) (NN type) (NN malignancy))))) |ET| |BS|390:G04.299.139.399 498:D01.210.375|ES| 2:1 18:1 19:1 49:1 160:1 491:1 543:1 712:1 1317:1 1691:1 1760:1 1761:1 1763:1 2304:1 2527:1 3867:1
1 	|BT| (NP (NP (NNP Thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NN dihydropyrimidine) (NN dehydrogenase) (NN expression)) (, ,) (NP (JJ histological) (NN tumour) (NN regression) (JJ 5-FU-based) (JJ neo-adjuvant) (JJ chemoradiotherapy) (JJ rectal) (NN cancer))) |ET| |BS|8:C04 333:D01.045 560:D03.383.742.698.875.404 561:E02.186.079.500 713:D08.811.913.555.500.862 846:F01.393.784 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350|ES| 2:1 18:1 19:1 66:1 115:1 1011:1 1986:1 1987:1 1988:1 1989:1 3002:1 3081:1 3082:1 3083:1 3084:1 3085:1 3086:1
1 	|BT| (S (NP (JJ Tolfenamic) (NN acid)) (ADVP (RB also)) (VP (VP (VBD facilitated) (NP (NP (NN translocation) (JJ endogenous) (JJ exogenous) (NN ESE-1) (NN nucleus)) (JJ colorectal) (NN cancer) (NN cell) (, ,) (NN gene) (NN silencing)) (S (VP (VBG using) (NP (NN ESE-1) (JJ small) (VBG interfering) (NN RNA))))) (VP (VBD attenuated) (NP (ADJP (JJ tolfenamic) (JJ acid-induced)) (NN EGR-1) (NN expression) (NN apoptosis))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 42:G05.355.315.203.374 117:D13.150.650.700 463:C23.550.210.870 580:D12.776.260.158.500 1104:A11.284.430.106|ES| 2:1 5:1 9:1 17:1 18:1 19:1 89:1 94:1 100:1 115:1 350:1 515:1 750:1 808:1 1275:1 1618:1 2598:1 2599:1 3019:1 3868:1 3869:1 3870:1 3871:1 3872:1 3873:1 3874:1
1 	|BT| (NP (NP (NN Transcription) (NN coactivator) (JJ PBP/MED1-deficient) (NNS hepatocytes)) (NP (JJ susceptible) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 209:G02.111.087.847 262:A11.436.348 554:D02.654.442.200 1105:D05.500.374.750|ES| 19:1 52:1 894:1 899:1 900:1 2732:1 2991:1 3875:1 3876:1
1 	|BT| (S (NP (NP (VBG Transforming) (NN growth) (NN factor-beta) (NN adaptor)) (, ,) (NP (NN beta2-spectrin)) (, ,)) (VP (VBZ modulates) (S (NP (NN cyclin) (JJ dependent) (NN kinase) (CD 4)) (VP (VB reduce) (NP (NN development) (JJ hepatocellular) (NN cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 503:D12.644.276.374.687 1106:D08.811.913.696.620.682.700.646.500.875 1107:D12.776.124.875|ES| 2:1 18:1 19:1 35:1 102:1 303:1 319:1 321:1 470:1 606:1 743:1 1773:1 2361:1 3877:1 3878:1 3879:1
1 	|BT| (S (NP (JJ Transgenic) (NN mouse) (VBG expressing) (NN cyclooxygenase-2) (NNS hepatocytes)) (VP (VBP reveal) (NP (JJ minor) (NN contribution) (NN enzyme) (NN chemical) (NN hepatocarcinogenesis)))) |ET| |BS|24:D08.811.600.720.750 99:B01.050.050.136.500 262:A11.436.348 730:D08.811 1108:M01.416|ES| 19:1 52:1 61:1 810:1 894:1 900:1 1360:1 1670:1 2124:1 2388:1 3880:1 3881:1
1 	|BT| (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (NN Loss) (NN E-cadherin)) (PRN (-LRB- -LRB-) (NP (NN CDH1)) (-RRB- -RRB-))) (, ,) (NP (NN Smad4)) (, ,) (NP (NP (NN p53) (VBN shown) (NN play) (JJ integral) (NN role)) (ADJP (JJ gastric))) (, ,) (NP (JJ intestinal) (, ,) (NN breast) (NN cancer) (NN formation)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200|ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1
1 	|BT| (S (PP (IN Unlike) (NP (NN celecoxib))) (, ,) (NP (NN sulindac)) (VP (VBD proved) (NP (ADJP (RB highly) (JJ effective)) (NN colon) (NN tumor) (NN prevention) (NN 15-PGDH) (NN KO) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 51:C04.588.274.476.411.307.180 251:D02.455.426.559.847.486.875 684:D02.065.884.247|ES| 2:1 7:1 19:1 52:1 113:1 133:1 626:1 869:1 1474:1 1639:1 2179:1 2807:1 2849:1 3882:1
1 	|BT| (S (NP (NP (NN Up-regulation) (JJ several) (NN miR-1) (NN target)) (PP (VBG including) (NP (NP (NN FoxP1)) (, ,) (NP (NN MET)) (, ,) (NP (NN HDAC4) (JJ primary) (JJ human) (NNS HCCs) (NP (NN down-regulation) (NN expression) (JJ 5-AzaC-treated) (NN HCC) (NN cell)))))) (VP (VBP suggest) (NP (NN role) (NN hepatocarcinogenesis)))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1
1 	|BT| (S (NP (JJ Ursodeoxycholic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN Ras) (NN mutation)) (, ,) (NP (NP (JJ wild-type) (NN Ras)) (NN activation)) (, ,) (NP (NN cyclooxygenase-2) (NN expression) (NN colon) (NN cancer))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 24:D08.811.600.720.750 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 8:1 18:1 19:1 34:1 61:1 113:1 115:1 225:1 615:1 1275:1 1775:1 3121:1
1 	|BT| (S (S (NP (JJ Ursolic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN metastasis) (JJ human) (JJ colorectal) (NN cancer) (JJ orthotopic) (JJ nude) (NN mouse) (NN model)) (VP (VBG targeting) (NP (JJ multiple) (NN cell) (NN signaling) (NN pathway)))))) (: :) (NP (NN chemosensitization) (NN capecitabine))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 113:C04.697.650 122:C14.280.383 126:G02.111.087.800 810:D03.383.742.680.245.500.425|ES| 17:1 18:1 19:1 36:1 52:1 72:1 94:1 102:1 104:1 195:1 266:1 383:1 615:1 616:1 649:1 806:1 1275:1 2873:1 3740:1 3883:1 3884:1
1 	|BT| (S (NP (NNP Use) (JJ novel) (JJ genetic) (NN mouse) (NN model)) (VP (VBP investigate) (NP (NN role) (NN folate) (JJ colitis-associated) (NN colon) (NN cancer)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 53:C06.405.205.265 224:D03.438.733.631.400 259:D12.776.395.240.150.500 1109:E05.599.395.397|ES| 18:1 19:1 31:1 52:1 72:1 113:1 410:1 459:1 778:1 864:1 891:1 3885:1
1 	|BT| (S (S (VP (VBG Using) (NP (JJ protein-protein) (NN interaction) (NN screening)))) (, ,) (VP (VBD found) (SBAR (S (NP (NN FOXO3a)) (VP (VBD interacted) (NP (NN ER-alpha) (NN ER-beta) (NN protein) (JJ human) (NN breast) (NN carcinoma) (NN cell) (NN line) (NN MCF-7)) (, ,) (S (VP (VBG suggesting) (VP (VBZ exists) (NP (NN crosstalk) (NN FOXO3a) (NN ER) (NN signaling) (NN pathway) (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell)))))))))) |ET| |BS|7:D12.776 126:G02.111.087.800 148:G12.425.143.281 432:A11.251.210.190.630 889:D27.505.696.399.472.277 1110:D12.776.826.750.350.174 1111:D12.776.826.750.350.262 1112:D23.125|ES| 2:1 4:1 18:1 19:1 23:1 36:1 37:1 94:1 195:1 224:1 264:1 304:1 383:1 618:1 741:1 1009:1 1188:1 1484:1 1719:1 3361:1 3362:1 3363:1 3886:1 3887:1 3888:1 3889:1
1 	|BT| (S (NP (PRP We)) (VP (VBD shown) (SBAR (S (NP (NN Hsp90) (NN inhibitor) (NN 17-AAG)) (VP (VBZ enhances) (NP (NN cytotoxicity) (NN oxaliplatin) (NN colon) (NN cancer) (NN cell) (NN line) (NN inhibition) (NN NF-kappaB))))))) |ET| |BS|43:F01.145.544 94:A11.251.210 210:D12.776.260.600 946:D27.888.569.213 1113:D12.776.580.216.380|ES| 18:1 19:1 94:1 103:1 113:1 237:1 264:1 380:1 714:1 843:1 1356:1 2543:1 3317:1 3890:1 3891:1
1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (S (NP (NN HT-29) (JJ human) (NN colon) (NN adenocarcinoma) (NN cell) (NN effect)) (VP (NN NO-ASA) (NP (NP (JJ inducible) (NN form) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN NOS2)) (-RRB- -RRB-))))) (, ,) (NN enzyme) (VBN implicated) (NN colon) (NN carcinogenesis)))) |ET| |BS|22:D08.811.682.664.500.772.500 33:C04.697.098 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 84:C04.557.470.200.025 189:V02.460 670:D02.455.426.559.389.657.410.595.176 730:D08.811 792:A11.251.210.190.475 1114:D08.811.277.352.827.070.250|ES| 2:1 10:1 14:1 19:1 36:1 63:1 64:1 65:1 66:1 75:1 94:1 113:1 207:1 255:1 324:1 630:1 843:1 977:1 2388:1 2782:1 3892:1 3893:1
1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NP (NP (NP (JJ antiangiogenic) (NN effect) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN copper) (NN chelator) (NN trientine)) (, ,) (S (VP (ADVP (RB especially)) (VBG focusing) (NP (NP (NN relationship) (NN copper) (NN interleukin-8)) (PRN (-LRB- -LRB-) (NP (NN IL-8)) (-RRB- -RRB-)))) (, ,) (NP (JJ potent) (JJ angiogenic) (NN factor)) (VP (VBN produced) (NP (NN hepatoma) (NN cell))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 515:C04.588.274.623 1084:D12.644.276.374.200.120.800 1085:D02.092.782.258.368.880 1086:D27.505.696.377.077.099 1087:D27.505.519.914.500 1088:D01.268.556.195 1115:D27.505.696.377.077.077 1116:G14.640.079|ES| 2:1 10:1 14:1 19:1 22:1 75:1 94:1 134:1 185:1 223:1 303:1 304:1 324:1 345:1 441:1 843:1 3790:1 3801:1 3802:1 3803:1 3804:1 3805:1 3894:1 3895:1 3896:1
1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN effect) (NN pioglitazone) (NN lung) (NN cancer) (NN development) (JJ carcinogen-induced) (NN lung) (NN adenocarcinoma) (NP (NP (JJ squamous) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN SCC)) (-RRB- -RRB-)))))) |ET| |BS|279:D27.888.569.100 929:C04.557.470.200.400|ES| 10:1 14:1 18:1 19:1 35:1 75:1 94:1 255:1 304:1 324:1 328:1 843:1 1067:1 2421:1 3897:1 3898:1
1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (SBAR (S (NP (NP (NP (NN role) (NN Se) (NNS selenoproteins) (NN liver) (NN tumor) (NN formation)) (NN TGFalpha/c-Myc) (JJ transgenic) (NN mouse)) (, ,) (NP (VBN characterized) (VBN disrupted) (NN redox) (NN homeostasis))) (VP (VBP develop) (NP (NN liver) (NN cancer) (CD 6) (NN month) (NN age))))))) |ET| |BS|15:F01.829.316.616 20:G03.495 99:B01.050.050.136.500 152:G07.700.345 515:C04.588.274.623 522:D12.644.276.382.750 865:G02.149.767.650 1073:D12.776.864 1117:Z01.639.520.750|ES| 2:1 7:1 18:1 19:1 31:1 43:1 52:1 285:1 324:1 500:1 648:1 836:1 843:1 985:1 2039:1 2723:1 3075:1 3529:1 3899:1 3900:1 3901:1 3902:1
1 	|BT| (S (NP (PRP We)) (VP (VBD found) (FRAG (NP (NN melatonin)) (ADVP (RB significantly)) (NP (VBD enhanced) (NP (JJ 5-FU-mediated) (NN inhibition) (NN cell) (NN proliferation)) (, ,) (NP (NP (NN colony) (NN formation)) (, ,) (NP (NN cell) (NN migration) (NN invasion) (NN colon) (NN cancer) (NN cell))))))) |ET| |BS|20:G03.495 41:A11 43:F01.145.544 109:I01.696.116 183:G04.299.233.750 560:D03.383.742.698.875.404 681:G04.299.283 707:D03.438.473.914.481|ES| 2:1 18:1 19:1 37:1 43:1 94:1 103:1 113:1 124:1 299:1 314:1 385:1 514:1 620:1 843:1 2556:1 3903:1
1 	|BT| (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (NP (NN treatment) (JJ COX2-overexpressing) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell) (NN fisetin)) (PRN (-LRB- -LRB-) (NP (CD 30-120) (NN microM)) (-RRB- -RRB-))) (VP (VBD resulted) (SBAR (S (NP (NP (NN induction) (NN apoptosis)) (, ,) (NP (NP (NN downregulation) (NN COX2) (NN protein) (NN expression)) (PP (IN without) (S (VP (VBG affecting) (NP (NN COX1))))))) (VP (VBD inhibited) (NP (NN secretion) (NN prostaglandin) (NN E2)))))))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 122:C14.280.383 792:A11.251.210.190.475 1118:D10.251.355.255.550.250.200 1119:D08.811.600.720.500 1120:A12.200|ES| 2:1 4:1 10:1 14:1 18:1 19:1 36:1 37:1 89:1 94:1 113:1 115:1 365:1 546:1 594:1 595:1 736:1 843:1 1195:1 2084:1 2530:1 2978:1 3017:1 3685:1 3904:1 3905:1 3906:1 3907:1 3908:1 3909:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD examined) (NP (NP (NP (NP (NP (NP (NN toxicity)) (FW vivo) (NP (NN efficacy) (NN lead) (NN diaminothiazole) (NN 4-Amino-5-benzoyl-2)) (: -)) (PRN (-LRB- -LRB-) (NP (JJ 4-methoxy) (NN phenylamino)) (-RRB- -RRB-))) (NN thiazole)) (PRN (-LRB- -LRB-) (NP (NN DAT1)) (-RRB- -RRB-))) (NN colon) (NN cancer) (NN xenograft)))) |ET| |BS|86:D01.268.556.435 92:E04.936.764 93:A01.941.875 1121:D02.886.675|ES| 5:1 10:1 14:1 18:1 19:1 113:1 254:1 265:1 324:1 378:1 843:1 2304:1 2406:1 3910:1 3911:1 3912:1 3913:1 3914:1 3915:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBN shown) (NP (NP (NN I3C) (JJ cyclic) (JJ tetrameric) (JJ derivative) (NN CTet)) (VP (VBN formulated) (NP (NP (NN gamma-cyclodextrin)) (PRN (-LRB- -LRB-) (NP (NN gamma-CD)) (-RRB- -RRB-))) (ADVP (RB efficiently)) (VP (VBD inhibited) (NP (JJ cellular) (NN proliferation) (NN breast) (NN cancer) (NN cell) (NN line))))))) |ET| |BS|41:A11 122:C14.280.383 776:G01.910.645 1122:B01.050.500.500.294.700.750.700.680|ES| 10:1 14:1 18:1 19:1 23:1 94:1 237:1 264:1 299:1 365:1 772:1 843:1 2813:1 3074:1 3916:1 3917:1 3918:1 3919:1 3920:1 3921:1 3922:1 3923:1
1 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (S (NP (NN PTK6) (NN inhibition) (JJ effective) (NN strategy)) (VP (VBP inhibit) (SBAR (S (NP (NP (NP (NP (NN growth) (NN survival) (NN Her2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN breast) (NN cancer) (NN cell)) (, ,) (PP (VBG including) (NP (ADJP (RB relatively) (JJ resistant)) (NNP Lapatinib))) (, ,)) (VP (VBN targeted) (NP (NP (NP (NP (NN therapy) (NN Her2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN breast) (NN cancer)) (, ,) (NP (CC either) (ADJP (RB intrinsically) (VBN acquired)) (JJ continuous) (NN drug) (NN exposure)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 43:F01.145.544 45:G07.700.320.249 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 67:D26 96:I03.784 122:C14.280.383|ES| 2:1 10:1 14:1 16:1 18:1 19:1 23:1 39:1 94:1 102:1 103:1 130:1 191:1 274:1 427:1 561:1 843:1 1041:1 1044:1 1114:1 1370:1 1639:1 1750:1 1953:1 3059:1 3924:1 3925:1 3926:1 3927:1 3928:1
1 	|BT| (S (NP (PRP We)) (VP (VP (VBD investigated) (NP (NP (NN colon) (NN cancer) (NN cell) (NN effect)) (NP (NN geraniol) (NN thymidylate) (NN synthase) (NN thymidine) (NN kinase) (NN expression)))) (, ,) (NP (CD two) (NN enzyme) (JJ related) (NN 5-fluorouracil) (NN cytotoxicity)))) |ET| |BS|41:A11 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 730:D08.811 946:D27.888.569.213 1123:D08.811.913.696.620.750|ES| 2:1 18:1 19:1 66:1 75:1 94:1 113:1 115:1 403:1 419:1 470:1 843:1 933:1 2307:1 2388:1 2578:1 3082:1 3317:1 3929:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NP (NN expression) (NN leptin) (NN receptor) (CD 171) (JJ consecutive) (NN patient)) (PRN (-LRB- -LRB-) (NP (NP (CD 78) (JJ female) (CD 93) (NN male)) (: ;) (NP (CD 71) (NN year))) (-RRB- -RRB-))) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 642:M01.975 1124:D06.472.699.042.500|ES| 10:1 14:1 19:1 115:1 120:1 186:1 217:1 245:1 403:1 843:1 1402:1 1404:1 1452:1 3206:1 3930:1 3931:1 3932:1 3933:1 3934:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (S (NP (JJ suppressive) (NN effect) (NN roxithromycin)) (VP (VBD accelerated) (NP (JJ hepatocellular) (NN carcinoma) (NN growth) (NN rat) (JJ hepatocarcinogenetic) (NN model)) (NP (VBN compared) (NN result) (NN effect) (NN TNP-470))))))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 843:D02.540.576.500.992.630|ES| 19:1 50:1 72:1 75:1 101:1 102:1 303:1 304:1 403:1 843:1 849:1 1391:1 1974:1 2990:1 3935:1 3936:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN lack) (NN fucosylation) (JJ consequent) (NN loss) (NN GDP-fucose) (NN synthesis)) (VP (VBZ contributes) (NP (NN colon) (NN carcinogenesis))))))) |ET| |BS|20:G03.495 33:C04.697.098 46:A03.556.124.526.356 1125:D03.438.759.646.454.340.350.400|ES| 19:1 32:1 113:1 207:1 221:1 252:1 403:1 843:1 845:1 3436:1 3937:1 3938:1 3939:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD demonstrated) (SBAR (S (NP (NN simvastatin)) (VP (VBZ inhibits) (NP (NP (NN NF-kappaB)) (SBAR (S (NP (NN signaling) (JJ human) (JJ intestinal) (JJ epithelial) (NN cell)) (VP (VBZ ameliorates) (NP (JJ acute) (JJ murine) (NN colitis))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 75:A11.436 122:C14.280.383 210:D12.776.260.600 754:D02.455.426.559.847.638.400.900|ES| 19:1 36:1 90:1 94:1 109:1 127:1 143:1 195:1 615:1 627:1 714:1 843:1 1175:1 1527:1 2679:1 2877:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NP (NP (NP (JJ anthocyanin-containing) (JJ baked) (JJ purple-fleshed) (NN potato)) (PRN (-LRB- -LRB-) (NP (NN PP)) (-RRB- -RRB-))) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN PA)) (-RRB- -RRB-))) (VP (VBD suppressed) (SBAR (S (NP (JJ early) (JJ advanced) (JJ human) (NN colon) (NN cancer) (NN cell) (NN proliferation)) (VP (VBD induced) (NP (NP (NN apoptosis)) (, ,) (NP (NP (NN effect) (NN colon) (NNS CSCs)) (ADJP (VBN known)))))))))))) |ET| |BS|39:G04.299.139.160 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 183:G04.299.233.750 556:C11.768.175 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087 1126:Z01.639.760.590.715 1127:Z01.107.757.656|ES| 2:1 10:1 14:1 18:1 19:1 36:1 75:1 89:1 94:1 113:1 132:1 299:1 307:1 412:1 556:1 843:1 997:1 1128:1 1527:1 1966:1 2439:1 2440:1 2496:1 3940:1 3941:1 3942:1 3943:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NN embelin)) (VP (VBZ inhibits) (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN vitro))))) (, ,) (VP (ADVP (RB effectively)) (VBZ suppresses) (NP (JJ 1,2-dimethylhydrazine) (JJ dihydrochloride-induced) (NN colon) (NN carcinogenesis) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383|ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1
1 	|BT| (S (NP (PRP We)) (VBP suggest) (NP (NN inosine) (CD 5)) ('' ') (: -) (NP (NP (NN monophosphate) (NN dehydrogenase) (NN inhibitor)) (, ,) (VP (ADVP (RB already)) (VBN used) (NP (NN treatment) (NN disease)))) (, ,) (VP (MD may) (NP (VBN used) (JJ potential) (NN differentiation) (NN therapy) (NN drug) (NN control) (NN prostate) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 74:G04.299.151 288:C23.550.288 1128:D08.811.682.047.820.450 1129:E02.319|ES| 2:1 18:1 19:1 77:1 130:1 191:1 215:1 289:1 380:1 476:1 491:1 546:1 796:1 827:1 843:1 998:1 3085:1 3944:1 3945:1 3946:1
1 	|BT| (S (NP (PRP We)) (VP (VBD tested) (S (NP (NP (NP (NN role) (JJ basic) (NN fibroblast) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN bFGF)) (-RRB- -RRB-))) (NP (JJ vascular) (NP (NP (JJ endothelial) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-))))) (VP (VBP switch) (NP (JJ angiogenic) (NN phenotype)) (NP (CD 35) (NN patient) (JJ colorectal) (NN cancer) (JJ different) (NN stage) (NN disease)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 80:G05.695 288:C23.550.288 371:A07.231 1067:D12.644.276.624.120 1130:D12.644.276.390|ES| 10:1 14:1 17:1 18:1 19:1 31:1 102:1 120:1 185:1 236:1 414:1 843:1 998:1 1129:1 1251:1 2066:1 2213:1 2709:1 2988:1 3092:1 3733:1 3790:1 3947:1 3948:1
1 	|BT| (SINV (IN While) (NP (JJ exact) (NN mechanism)) (-LRB- -LRB-) (S (NP (-RRB- -RRB-) (NN antitumor) (NN activity) (NN p-XSC)) (VP (VBZ remains) (VP (VBN elucidated)))) (, ,) (VP (VBZ appears)) (NP (NP (NN modulation) (NN beta-catenin) (NN expression) (NN COX-2) (NN activity)) (VBN associated) (NN inhibition) (JJ intestinal) (NN polyp))) |ET| |BS|23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 193:C23.300.825.411|ES| 2:1 10:1 14:1 19:1 60:1 76:1 103:1 109:1 115:1 162:1 169:1 399:1 442:1 647:1 1945:1 2244:1 3949:1 3950:1 3951:1 3952:1 3953:1
1 	|BT| (S (NP (NP (NN Zinc-finger) (NN protein) (CD 331)) (, ,) (NP (JJ novel) (JJ putative) (NN tumor) (NN suppressor)) (, ,)) (VP (VBZ suppresses) (NP (NN growth) (NN invasiveness) (JJ gastric) (NN cancer)))) |ET| |BS|7:D12.776 45:G07.700.320.249 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500 1131:G02.111.570.820.709.600.040.985|ES| 2:1 4:1 7:1 18:1 19:1 86:1 102:1 686:1 700:1 891:1 918:1 3954:1 3955:1 3956:1
-1 	|BT| (NP (NP (JJ Possible) (NN involvement) (JJ oxidative) (NN stress) (JJ fenofibrate-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 916:D02.241.081.114.968.500.625|ES| 19:1 636:1 849:1 900:1 2522:1 2583:1 4333:1 4334:1
-1 	|BT| (S (NP (JJ Possible) (NN involvement) (JJ oxidative) (NN stress) (NN piperonyl) (NN butoxide)) (VP (VBD induced) (NP (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 1077:D03.383.246.118.600|ES| 19:1 412:1 636:1 849:1 900:1 2522:1 2583:1 3777:1 3778:1 4333:1
-1 	|BT| (S (NP (NNP Prevention) (JJ azoxymethane/dextran) (NN sodium) (JJ sulfate-induced) (NN mouse) (NN colon) (NN carcinogenesis)) (VP (VBN processed) (NP (NNP Aloe) (NN vera) (NN gel)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080|ES| 19:1 52:1 113:1 207:1 405:1 407:1 674:1 2898:1 4025:1 4026:1 4027:1 4335:1
-1 	|BT| (NP (NP (JJ Protective) (NN effect) (NN dioscin) (JJ alcohol-induced) (NN liver) (NN injury))) |ET| |BS|242:A03.620 751:D02.033.375 822:D02.033|ES| 19:1 75:1 836:1 2416:1 2672:1 2909:1 2910:1
-1 	|BT| (NP (NP (NP (NP (NN ra) (NN proto-oncogene) (NN activation) (JJ dichloroacetic) (NN acid)) (: -) (, ,) (NP (NN trichloroethylene)) (: -)) (JJ tetrachloroethylene-induced) (NN liver) (NN tumor) (NN B6C3F1) (NN mouse))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 11:B01.050.150.900.649.865.635.505.500 235:G05.360.340.024.340.375.500.791 515:C04.588.274.623 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939 1236:D02.455.526.439.880|ES| 2:1 7:1 19:1 52:1 225:1 563:1 836:1 1115:1 3986:1 4273:1 4336:1 4337:1 4338:1
-1 	|BT| (S (NP (NNS Rats)) (VP (VBD received) (SBAR (S (NP (NP (JJ weekly) (JJ intraperitoneal) (NN injection) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD followed) (NP (NP (JJ 2-week) (JJ wash-out) (NN period)) (VP (VBD caused) (NP (NP (NN cirrhosis) (CD 14) (NN week)) (JJ multifocal) (NN HCC) (CD 18) (NN week))))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 554:D02.654.442.200 662:C23.550.355 776:G01.910.645 917:E02.319.267.530.490|ES| 10:1 14:1 19:1 441:1 783:1 785:1 1199:1 1440:1 1875:1 1952:1 2506:1 2725:1 3130:1 3230:1 3266:1 3664:1 3714:1 4076:1 4339:1 4340:1 4341:1
-1 	|BT| (NP (NP (VBN Reduced) (NP (NN susceptibility) (JJ azoxymethane-induced) (JJ aberrant) (NN crypt) (NN focus) (NN formation) (NN colon) (NN cancer) (NN growth) (NN hormone) (JJ deficient) (NN rat)))) |ET| |BS|20:G03.495 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 401:C23.550.291.687 824:C04.834.020 1237:D06.472.699.631.525.425.875 1238:D06.472.699.631.525.425|ES| 18:1 19:1 43:1 102:1 113:1 542:1 849:1 1353:1 1431:1 1504:1 1531:1 1725:1 2533:1 2913:1
-1 	|BT| (NP (NP (NN Regulation) (NN iron) (JJ metabolism-related) (NN gene) (JJ diethylnitrosamine-induced) (NN mouse) (NN liver) (NN tumor))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 140:G05.355.315 515:C04.588.274.623 554:D02.654.442.200 895:D01.490.600 896:D01.268.556.412 898:G03.495|ES| 7:1 9:1 19:1 52:1 699:1 836:1 2732:1 3162:1 4342:1
-1 	|BT| (S (S (NP (NN Reporter) (NN mouse) (VBN given) (NN azoxymethane)) (VP (VBD followed) (S (NP (NN dextran) (NN sulfate) (NN sodium)) (VP (VBP induce) (NP (NN colitis) (NN colon) (NN tumor)))))) (: ;) (S (NP (NN mouse)) (VP (VBN given) (NP (NNP ROCK) (NN inhibitor) (NN fasudil)) (PP (IN along) (NP (NP (NN agent)) (PRN (-LRB- -LRB-) (NP (NN ROCK) (NN inhibitor) (NN increase) (NN miRNA) (NN function)) (-RRB- -RRB-))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 53:C06.405.205.265 131:D09.698.365.272.300 132:D02.172.080 184:D13.150.650.319|ES| 7:1 10:1 14:1 19:1 29:1 33:1 40:1 52:1 113:1 143:1 217:1 243:1 380:1 406:1 407:1 728:1 840:1 1993:1 2666:1 3130:1 3300:1 4343:1 4344:1 4345:1
-1 	|BT| (S (NP (NNS Results) (NN study)) (VP (VBP demonstrate) (SBAR (S (NP (NP (NN PPARalpha)) (VP (VBN required))) (VP (VBP mediate) (NP (NP (NN hepatocarcinogenesis) (VBD induced) (NN bezafibrate)) (, ,) (S (NP (NN PPARalpha)) (VP (VBZ protects) (NP (JJ potential) (NN cholestasis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 535:H01.770.644.145.431 536:D12.776.826.239.500 879:C06.130.120.135 909:D02.065.277.067|ES| 2:1 19:1 131:1 412:1 502:1 702:1 827:1 900:1 1176:1 1601:1 1863:1 3201:1 4115:1 4131:1
-1 	|BT| (NP (NP (NNS RESULTS) (: :)) (UCP (S (NP (NN Deletion) (NN Tgfbr2) (NN liver) (JJ epithelial) (NN cell)) (VP (VBP alter) (NP (NN liver) (NN injury)))) (, ,) (NP (NP (JJ toxin-induced) (JJ biliary) (NN fibrosis)) (, ,) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis))))) |ET| |BS|242:A03.620 262:A11.436.348 306:G05.355.600.800 554:D02.654.442.200 691:C23.550.355 1239:A12.200.087 1240:D23.946|ES| 2:1 19:1 94:1 104:1 127:1 710:1 836:1 900:1 949:1 2416:1 2732:1 4152:1 4346:1 4347:1 4348:1 4349:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN Silibinin) (NN feeding)) (VP (VBD showed) (NP (NP (ADJP (NP (JJ dose-dependent) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)) (JJR stronger)) (NN efficacy) (NN pretreatment)) (CC versus) (NP (NN posttreatment) (NNS regimen))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 532:E02.183|ES| 19:1 78:1 104:1 113:1 132:1 295:1 710:1 1881:1 1983:1 2304:1 2531:1 2533:1 2824:1 2942:1 2943:1 2944:1 2945:1
-1 	|BT| (S (NP (NNS RESULTS)) (: :) (S (NP (PRP We)) (VP (VBD uncovered) (SBAR (S (NP (NN adrenaline)) (VP (VBD promoted) (NP (JJ DEN-induced) (NN hepatocarcinogenesis))))))) (, ,) (VP (VBD reversed) (NP (NN ADRB2) (NN antagonist) (NN ICI118) (CD ,551)))) |ET| |BS|1241:D12.776.543.750.069.300.300.340.200 1242:D02.033.100.291.310|ES| 2:1 19:1 104:1 710:1 843:1 900:1 1271:1 1912:1 2735:1 4350:1 4351:1 4352:1 4353:1 4354:1
-1 	|BT| (NP (NP (NN Role) (NN CYP2E1) (JJ diethylnitrosamine-induced) (FW hepatocarcinogenesis) (FW vivo))) |ET| |BS|15:F01.829.316.616 554:D02.654.442.200 1218:D08.244.453.300|ES| 19:1 378:1 900:1 2187:1 2732:1 4270:1
-1 	|BT| (NP (NP (NN Role) (NN Nrf2) (JJ oxidative) (NN stress) (JJ fenofibrate-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|15:F01.829.316.616 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 799:D12.776.260.615.249 916:D02.241.081.114.968.500.625|ES| 19:1 849:1 900:1 2187:1 2522:1 2583:1 4334:1 4355:1
-1 	|BT| (NP (NP (NN Role) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor-alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARalpha)) (-RRB- -RRB-))) (JJ bezafibrate-induced) (NN hepatocarcinogenesis) (NN cholestasis))) |ET| |BS|15:F01.829.316.616 536:D12.776.826.239.500 879:C06.130.120.135 909:D02.065.277.067|ES| 10:1 14:1 19:1 900:1 1801:1 1887:1 1889:1 2187:1 4115:1 4131:1 4356:1
-1 	|BT| (NP (NP (NP (NP (NN Role) (NN life) (NN span) (NN determinant) (NN P66)) (PRN (-LRB- -LRB-) (NP (NN shcA)) (-RRB- -RRB-))) (JJ ethanol-induced) (NN liver) (NN damage))) |ET| |BS|15:F01.829.316.616 242:A03.620 751:D02.033.375 1243:K01.752.400|ES| 10:1 14:1 19:1 836:1 1848:1 2187:1 2674:1 4357:1 4358:1 4359:1 4360:1 4361:1
-1 	|BT| (S (ADVP (RB Second)) (, ,) (NP (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NP (NP (NN CCl) (-LRB- -LRB-) (CD 4) (-RRB- -RRB-)) (: ;) (NP (NP (NP (CD 0.2) (NN ml/kg)) (, ,) (NP (JJ 2/week) (NN ip))) (VP (VBG starting) (NP (CD 8) (NN week) (NN age)))) (-RRB- -RRB-)) (VP (VBN administered) (NP (CD 9) (CD 14) (NN week)))) (VP (VBP develop) (NP (JJ advanced) (NN liver) (NN fibrosis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 113:C04.697.650 676:C06.552.630 1025:Z01.252.100.450 1217:A02.513.514.100 1220:D02.455.526.439.150|ES| 2:1 10:1 14:1 19:1 217:1 319:1 648:1 781:1 783:1 836:1 949:1 997:1 1440:1 2336:1 2717:1 3902:1 4261:1 4278:1 4279:1 4362:1 4363:1 4364:1 4365:1 4366:1
-1 	|BT| (NP (NP (NP (JJ Selective) (NN pressure) (NN tumor) (NN promotion)) (NP (JJ phenobarbital) (NN lead) (JJ clonal) (NN outgrowth) (JJ beta-catenin-mutated) (NN mouse) (NN liver) (NN tumor)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 86:D01.268.556.435 301:A11.251.353 515:C04.588.274.623 756:D03.383.742.698.253.650 1244:G01.374.715|ES| 7:1 19:1 52:1 254:1 836:1 1069:1 2337:1 2685:1 4031:1 4367:1 4368:1 4369:1
-1 	|BT| (S (NP (NP (CD SP600125)) (, ,) (NP (NN JNK) (NN inhibitor)) (, ,)) (VP (VBD reported) (NP (NN block) (JJ acetaminophen-induced) (NN liver) (NN injury)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 122:C14.280.383 242:A03.620 661:D02.065.199.092.040|ES| 2:1 19:1 380:1 742:1 836:1 993:1 2411:1 2416:1 4113:1 4276:1
-1 	|BT| (S (NP (DT The) (NN parameter)) (NP (JJ related) (JJ key) (NN event) (JJ Metofluthrin-induced) (NN liver) (NN tumor)) (VP (VBD observed) (NP (JJ tumorigenic) (NN dose) (NN level)))) |ET| |BS|515:C04.588.274.623|ES| 7:1 19:1 159:1 205:1 249:1 261:1 419:1 691:1 836:1 1809:1 2301:1 4370:1 4371:1
-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP examine) (NP (NP (NP (JJ anti-cancer) (JJ anti-fibrotic) (NN effect) (NN BCAA) (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VBN induced) (NN HCC) (NN liver) (NN cirrhosis) (NN rat) (NN model)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 554:D02.654.442.200 691:C23.550.355|ES| 10:1 14:1 19:1 35:1 72:1 75:1 131:1 409:1 441:1 691:1 836:1 849:1 960:1 1112:1 1199:1 1567:1 1875:1 1952:1 2360:1 4372:1
-1 	|BT| (FRAG (NP (NP (DT The) (NN aim) (NN work)) (VBP characterize) (NP (NP (NN effect) (NN CAPE) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (VBN involved) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NN metabolism) (NN initiation) (NN stage) (NN chemical) (NN hepatocarcinogenesis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 445:I03.946 554:D02.654.442.200 898:G03.495 1079:D08.244.453|ES| 2:1 10:1 14:1 19:1 75:1 637:1 691:1 774:1 900:1 1129:1 1546:1 1567:1 1875:1 1952:1 2124:1 2252:1 2332:1 2549:1 3163:1 3788:1 3789:1
-1 	|BT| (S (NP (DT The) (NN conclusion) (NN evaluation) (JJ pronamide-induced) (NN mouse) (NN liver) (NN tumor)) (VP (VBP occur) (PP (IN via) (NP (NP (JJ NR-mediated) (NN MoA)) (VP (VBG involving) (NP (NP (NN CAR) (NN PPAR-alpha) (NN activation) (NN MoA) (JJ relevant) (JJ human) (VBN based) (JJ qualitative/quantitative) (NN difference) (NN mouse)) (ADJP (JJ human)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 139:J01.937.500.100 225:E05.337 333:D01.045 515:C04.588.274.623 536:D12.776.826.239.500 1245:Z01.639.760.680|ES| 7:1 19:1 36:1 52:1 225:1 421:1 596:1 691:1 836:1 865:1 1284:1 1674:1 2044:1 2503:1 4055:1 4070:1 4373:1 4374:1 4375:1 4376:1 4377:1
-1 	|BT| (NP (NP (DT The) (NN correlation) (NN body) (NN growth) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN relation) (NN serum) (NN insulin) (NN somatomedin-C))) |ET| |BS|45:G07.700.320.249 554:D02.654.442.200 598:D12.644.276.937.400 637:D06.472.699.587.200.500.625 782:A12.207.152.846 1246:I01.076.201.450.560|ES| 19:1 102:1 691:1 900:1 1678:1 2364:1 2398:1 2732:1 2741:1 3544:1 4378:1
-1 	|BT| (S (NP (NP (DT The) (NN effect) (NN D-allose) (NN diethyl) (NN nitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NP (NN hepatocarcinogenesis) (VBN examined) (JJ male) (NN F344) (NN rat) (NN rat) (JJ medium-term) (NN bioassay)) (VP (VBN based) (NP (NP (JJ two-step) (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (NN experiment) (CD 1)) (-RRB- -RRB-))))))) |ET| |BS|106:E05.091 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 333:D01.045 554:D02.654.442.200 590:B01.050.050.199.520.760.200 849:G08.686.785.760.769.490.500 914:L01.178|ES| 10:1 14:1 19:1 72:1 75:1 98:1 324:1 409:1 691:1 849:1 900:1 1402:1 1514:1 1875:1 2632:1 2931:1 3185:1 3215:1 3625:1 4070:1 4249:1 4379:1
-1 	|BT| (NP (NP (DT The) (NN gene) (NN expression) (JJ hepatic) (NN protein) (JJ responsible) (NN DNA) (NN repair) (NN cell) (NN proliferation) (JJ tamoxifen-induced) (NN hepatocarcinogenesis))) |ET| |BS|183:G04.299.233.750 640:D02.455.426.559.389.150.700.900 1134:G02.111.087.219 1213:D12.776|ES| 4:1 9:1 19:1 94:1 115:1 299:1 513:1 666:1 691:1 838:1 900:1 2132:1 3966:1
-1 	|BT| (S (S (NP (DT The) (NN goal) (JJ present) (NN study)) (-LRB- -LRB-) (-RRB- -RRB-) (VP (VBP investigate) (NP (NN mechanism) (NN resistance) (NN mouse) (JJ tamoxifen-induced) (NN hepatocarcinogenesis)))) (, ,) (S (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (VP (VB clarify) (NP (NN effect) (NN tamoxifen) (JJ NAFLD-associated) (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 415:F01.658.500 577:C06.552.241.519 640:D02.455.426.559.389.150.700.900 967:D01.248.497.158.490|ES| 2:1 10:1 14:1 19:1 52:1 75:1 131:1 162:1 459:1 691:1 836:1 900:1 1094:1 1307:1 2371:1 2416:1 3193:1 3966:1 4380:1 4381:1 4382:1
-1 	|BT| (S (NP (NP (NP (DT The) (JJR higher) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 450) (NN ppm)) (-RRB- -RRB-))) (NN cyproconazole)) (VP (VBD caused) (NP (NP (JJ similar) (NN change)) (, ,) (NP (NP (JJR greater) (NN evidence) (NN liver) (NN damage)) (VP (VBN observed) (, ,) (PP (VBG including) (NP (JJ large) (NN increase) (NN plasma) (NN transaminase)))))))) |ET| |BS|242:A03.620 657:A12.207.152.693 781:D08.811.913.477.700|ES| 2:1 10:1 14:1 19:1 38:1 40:1 170:1 200:1 261:1 332:1 561:1 691:1 836:1 1848:1 2204:1 2301:1 2400:1 2506:1 2742:1 3233:1 4073:1 4255:1 4383:1
-1 	|BT| (S (S (NP (DT The) (JJ knockout) (NN animal)) (VP (VBD increased) (NP (NP (NN lipid) (NN peroxidation)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ CCl4-induced) (NN liver) (NN damage)) (, ,) (PP (ADVP (RB largely)) (JJ due) (NP (NP (VBN increased) (NN CYP2E1) (NN expression) (NN diallyl) (NN sulfide)) (, ,) (NP (NN inhibitor) (NN CYP2E1)) (, ,))))))) (VP (VBD prevented) (NP (JJ CCl4-induced) (NN liver) (NN injury)))) |ET| |BS|12:Z01.542.049 19:B01.050 242:A03.620 1218:D08.244.453.300 1247:G02.111.087.520|ES| 2:1 19:1 46:1 47:1 71:1 115:1 380:1 385:1 607:1 691:1 836:1 1848:1 1944:1 2401:1 2416:1 2520:1 2595:1 2851:1 4270:1 4384:1 4385:1 4386:1
-1 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBP examine) (SBAR (S (NP (NN effect) (NN pharmacology) (NN PARP-1) (NN inhibition) (NN reduction) (NN tumor) (NN volume) (NN HCC) (NN xenograft) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (NN diethyl-nitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 415:F01.658.500 554:D02.654.442.200 1059:H01.158.703 1203:E05.041.124.892 1248:D08.811.913.400.725.115.690|ES| 7:1 10:1 14:1 19:1 75:1 103:1 131:1 265:1 370:1 412:1 441:1 691:1 900:1 960:1 1875:1 2916:1 3589:1 4387:1 4388:1 4389:1
-1 	|BT| (NP (NP (NP (DT The) (JJ orphan) (JJ nuclear) (NN receptor) (JJ constitutive) (NN active/androstane) (NN receptor)) (JJ essential) (NN liver) (NN tumor) (NN promotion) (JJ phenobarbital) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 38:Z01.058.290.120.180 40:Z01.542.248.700 515:C04.588.274.623 604:M01.108 756:D03.383.742.698.253.650 950:D12.776.826 1249:D04.808.054|ES| 7:1 19:1 52:1 186:1 604:1 691:1 836:1 1256:1 1776:1 2217:1 2337:1 2685:1 4390:1
-1 	|BT| (S (NP (DT The) (JJ overall) (NN commonality) (NN expression)) (SYM AOX) (: -) (: /) (: -) (NP (JJ ciprofibrate-induced) (NN liver) (NN tumor) (JJ DENA-induced) (NN tumor)) (VP (ADVP (RB strongly)) (VBZ implicates) (NP (NP (NN activation) (NN PPARalpha) (JJ PPARalpha-regulated) (NN gene) (NN liver)) (, ,) (PP (VBG including) (S (VP (VBG participating) (NP (NN lipid) (NN catabolism)))))) (, ,) (FRAG (NP (JJ key) (NN factor) (NN development) (NN HCC)) (SYM AOX) (: -) (: /) (: -) (NP (JJ ciprofibrate-treated) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 52:E02 104:C04.557.470.200.025.255 142:I01.880.604 242:A03.620 515:C04.588.274.623 536:D12.776.826.239.500 554:D02.654.442.200 696:V02.270.500 1250:G02.111.087.530|ES| 2:1 7:1 9:1 19:1 35:1 52:1 115:1 159:1 185:1 225:1 441:1 561:1 635:1 691:1 836:1 2401:1 2510:1 3026:1 4115:1 4321:1 4324:1 4391:1 4392:1 4393:1 4394:1 4395:1 4396:1
-1 	|BT| (NP (NP (DT The) (JJ present) (NN study)) (VP (VBN aimed) (VP (VBP investigate) (NP (NP (NP (NP (NN efficacy) (NN thymoquinone)) (PRN (-LRB- -LRB-) (NP (NN TQ)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ active) (NN compound)) (VP (VBN derived) (NP (JJ medicinal) (NN plant) (NNP Nigella) (NN sativa)))) (, ,) (NP (NP (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN NDEA)) (-RRB- -RRB-)))) (PRN (-LRB- -LSB-) (NP (ADJP (CD 0.01) (NN %)) (NN drinking) (NN water) (CD 16) (NN week)) (-RRB- -RSB-))))) (NP (: -) (VBN induced) (NN hepatocarcinogenesis) (JJ experimental) (NN rat))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1060:D01.045.250.875.300 1251:B01.650.940.800.575.100.838.518.750 1252:B01.650.560|ES| 2:1 10:1 14:1 19:1 131:1 197:1 263:1 315:1 369:1 409:1 459:1 460:1 691:1 783:1 844:1 849:1 900:1 1098:1 1307:1 1373:1 1378:1 1721:1 2304:1 2433:1 2602:1 3234:1 3796:1 3968:1 3997:1 4295:1 4397:1 4398:1 4399:1
-1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBN designed) (VP (VBP investigate) (SBAR (S (NP (NP (JJ hepatoprotective) (NN effect) (NN plant) (NN extract) (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))) (VP (VBD induced) (NP (NN hepatocyte) (NN damage) (NN vitro) (NN liver) (NN injury)) (FW vivo))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 262:A11.436.348 328:B01.650 1220:D02.455.526.439.150|ES| 10:1 14:1 19:1 75:1 131:1 216:1 378:1 412:1 459:1 691:1 836:1 1098:1 1307:1 1683:1 1848:1 1909:1 2416:1 2496:1 4278:1 4279:1 4280:1 4400:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VBP investigate) (FRAG (NP (NP (JJ chemopreventive) (NN action) (JJ possible) (NN mechanism) (NN saffron) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN liver) (NN cancer) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 701:B01.650.940.800.575.100.549.500|ES| 10:1 14:1 18:1 19:1 162:1 409:1 459:1 691:1 836:1 849:1 1359:1 1497:1 1875:1 1946:1 1952:1 2013:1 2523:1 3011:1
-1 	|BT| (NP (NP (DT The) (NN result) (NN show) (NN tamoxifen)) (, ,) (NP (NN toremifene)) (, ,) (NP (JJ potential) (S (VP (VBP induce) (VP (VBP promote) (NP (NN development) (NN rat) (NN hepatocarcinogenesis) (JJ experimental) (NN model))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 95:E05.599 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900 1253:D02.455.426.559.389.150.700.900.900|ES| 2:1 19:1 35:1 72:1 101:1 243:1 263:1 429:1 679:1 691:1 827:1 849:1 900:1 2371:1 4401:1
-1 	|BT| (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN effect)) (NP (ADJP (RB orally) (JJ bioavailable)) (JJ synthetic) (NN triterpenoid) (NN 2-cyano-3,12-dioxooleana)) (: -) (NP (CD 1,9) (-LRB- -LRB-) (CD 11) (-RRB- -RRB-) (: -)) (NP (NP (NN dien-28-oate-ethyl) (NN amide)) (PRN (-LRB- -LRB-) (NP (NP (NN CDDO-EA)) (, ,) (NP (NN RTA) (CD 405))) (-RRB- -RRB-))) (, ,) (NP (JJ potent) (JJ antioxidative) (JJ antiinflammatory) (NN property))) (, ,) (VP (VBD evaluated) (S (NP (JJ chronic) (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NN CCl) (PRN (-LRB- -LRB-) (CD 4) (-RRB- -RRB-) (-RRB- -RRB-)) (: -)) (VP (VBN induced) (NP (NP (NN model) (NN liver) (NN cirrhosis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 357:C06.552.630 686:D27.505.954.158 1217:A02.513.514.100 1220:D02.455.526.439.150 1254:D02.241.081.018.386.682.300 1255:G03.787.151 1256:D02.065|ES| 2:1 10:1 14:1 19:1 22:1 72:1 75:1 303:1 304:1 319:1 409:1 441:1 780:1 836:1 841:1 1057:1 1199:1 1620:1 1790:1 2477:1 3218:1 3224:1 4226:1 4261:1 4278:1 4279:1 4402:1 4403:1 4404:1 4405:1 4406:1 4407:1 4408:1 4409:1 4410:1
-1 	|BT| (S (ADVP (RB Therefore)) (, ,) (NP (NN study)) (VP (VBD initiated) (VP (VB investigate) (SBAR (IN whether) (S (NP (NP (NP (NN thymoquinone)) (PRN (-LRB- -LRB-) (NP (NN TQ)) (-RRB- -RRB-))) (, ,) (NP (NNP Nigella) (NN sativa) (NN derived-compound) (JJ strong) (JJ antioxidant) (NN property)) (, ,) (NP (NN supplementation))) (VP (MD could) (VP (VB prevent) (NP (NP (NP (NN initiation) (JJ hepatocarcinogenesis-induced) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DENA)) (-RRB- -RRB-))) (, ,) (NP (JJ potent) (NN initiator) (NN hepatocarcinogen)) (, ,) (NP (NN rat)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 700:D27.505.519.217 1251:B01.650.940.800.575.100.838.518.750 1257:G07.265.500|ES| 2:1 10:1 14:1 19:1 22:1 131:1 221:1 459:1 460:1 637:1 733:1 841:1 849:1 908:1 1620:1 1900:1 1952:1 2521:1 2567:1 2644:1 3578:1 3796:1 4398:1 4399:1 4411:1 4412:1 4413:1 4414:1
-1 	|BT| (S (NP (NP (DT These) (NN alteration)) (, ,) (NP (NN hallmark) (JJ human) (NN colon) (NN cancer)) (, ,)) (ADVP (RB probably)) (VP (VBD contributed) (NP (NN pathogenesis) (JJ large) (JJ intestinal) (NN carcinoma) (NN mouse)) (PP (VBG following) (NP (JJ o-nitrotoluene) (NN exposure))))) |ET| |BS|5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 18:1 19:1 36:1 52:1 109:1 113:1 304:1 501:1 792:1 951:1 1427:1 1953:1 3510:1 4073:1 4415:1 4416:1 4417:1
-1 	|BT| (S (NP (DT These) (NN finding) (, ,)) (S (VP (VP (VBN taken) (ADVP (RB together)) (ADVP (RB previously)) (VP (VBN reported) (S (VP (NN study))))) (, ,) (S (NP (NP (NN support) (NN mode) (NN action) (NN toxaphene)) (VP (VBD induced) (NP (NP (NN mouse) (NN liver) (NN tumor) (JJ nongenotoxic) (NN mechanism)) (VP (VBG involving) (NP (ADJP (RB primarily) (JJ CAR-mediated)) (NN process)))))) (VP (VBP result) (NP (NN increase) (NN cell) (NN proliferation) (NN liver)))))) (, ,) (VP (VBZ promotes) (NP (NP (JJ clonal) (NN expansion) (JJ preneoplastic) (NN lesion)) (VP (VBG leading) (NP (NN adenoma) (NN formation)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 20:G03.495 86:D01.268.556.435 139:J01.937.500.100 183:G04.299.233.750 242:A03.620 301:A11.251.353 515:C04.588.274.623 897:Z01.252.245.500.375 1149:D02.455.526.439.913|ES| 2:1 7:1 19:1 40:1 42:1 43:1 52:1 94:1 101:1 131:1 162:1 298:1 299:1 412:1 638:1 639:1 792:1 836:1 927:1 993:1 1069:1 1131:1 1362:1 1364:1 1438:1 1527:1 1538:1 1970:1 2013:1 3340:1 3985:1 4055:1 4418:1 4419:1 4420:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP argue) (S (NP (JJ intact) (NN HGF/c-Met) (NN signaling) (JJ essential)) (VP (VBG maintaining) (NP (NP (JJ normal) (NN redox) (NN homeostasis) (NN liver) (NN tumor) (NN suppressor) (NN effect)) (-LRB- -LRB-) (NP (-RRB- -RRB-) (JJ early) (NN stage) (JJ N-nitrosodiethylamine-induced) (NN hepatocarcinogenesis)))))))) |ET| |BS|69:G02.111.087.800 152:G07.700.345 188:N02.628 206:G05.360.340.024.340.375.249 242:A03.620 554:D02.654.442.200 865:G02.149.767.650|ES| 7:1 10:1 14:1 19:1 75:1 101:1 118:1 195:1 500:1 700:1 792:1 836:1 900:1 1128:1 1129:1 1776:1 2948:1 3075:1 4421:1 4422:1 4423:1 4424:1
-1 	|BT| (S (NP (NN Thioacetamide)) (VP (VBZ accelerates) (NP (NP (NN steatohepatitis)) (, ,) (NP (NP (NN cirrhosis) (NN HCC)) (VP (VBG expressing) (NP (NN HCV) (NN core) (NN protein) (JJ transgenic) (NN zebrafish) (NN Danio) (NN rerio))))))) |ET| |BS|104:C04.557.470.200.025.255 296:D02.065.064.786 352:B01.050.050.136 357:C06.552.630 508:C06.552.241 572:B01.050.150.900.493.200.244.828 662:C23.550.355|ES| 2:1 4:1 19:1 285:1 441:1 529:1 810:1 1199:1 1791:1 1938:1 2017:1 4425:1 4426:1 4427:1 4428:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBD evaluated) (SBAR (S (NP (JJ beneficial) (NN effect) (NN coffee) (NN caffeine) (JJ medium-term) (NN bioassay) (NN rat) (NN liver) (NN fibrosis/carcinogenesis)) (VP (VBD induced) (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NP (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))))))))) |ET| |BS|33:C04.697.098 106:E05.091 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 652:D20.215.784.249 676:C06.552.630 819:D03.132.960.175 849:G08.686.785.760.769.490.500 914:L01.178 1220:D02.455.526.439.150|ES| 10:1 14:1 19:1 75:1 131:1 412:1 780:1 807:1 836:1 849:1 984:1 1875:1 1952:1 2386:1 2899:1 2931:1 3215:1 4278:1 4279:1 4280:1 4429:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBN tested) (NP (NP (NN effectiveness) (NN SAM) (NN supplementation)) (VP (VBG protecting) (NP (NP (NN azoxymethane) (-LRB- -LRB-) (NN AOM) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN colon) (NN carcinogenesis) (JJ male) (NN F344) (NN rat)))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 232:D02.886.030.676.180 590:B01.050.050.199.520.760.200|ES| 10:1 14:1 19:1 113:1 131:1 207:1 409:1 807:1 849:1 1402:1 1993:1 1994:1 2567:1 2988:1 3185:1 3437:1 3573:1 4111:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBD performed) (VP (VB investigate) (SBAR (S (NP (NN mode) (NN action) (NN toxaphene)) (VP (VBD induced) (NP (NN mouse) (NN liver) (NN tumor)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 7:1 19:1 52:1 131:1 412:1 458:1 459:1 807:1 836:1 2013:1 3985:1 4419:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (ADJP (RB highly) (JJ likely)) (NNP MOA) (JJ Metofluthrin-induced) (NN liver) (NN tumor) (NN rat) (NN CYP) (NN induction)) (VP (VBD increased) (NP (NN hepatocyte) (NN proliferation)) (, ,) (NP (JJ similar) (VBN seen) (NN phenobarbital)))) |ET| |BS|213:F02.830.816.964 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 515:C04.588.274.623 756:D03.383.742.698.253.650 897:Z01.252.245.500.375|ES| 2:1 7:1 19:1 47:1 299:1 332:1 626:1 724:1 736:1 836:1 849:1 1328:1 1691:1 1909:1 2685:1 3342:1 3789:1 4371:1
-1 	|BT| (S (NP (NN Thymoquinone)) (VP (VBZ inhibits) (NP (NP (NN cell) (NN proliferation) (NN regulation) (NN G1/S) (NN phase) (NN cell) (NN cycle) (NN transition)) (NP (JJ N-nitrosodiethylamine-induced) (JJ experimental) (NN rat) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 757:C04.588.274.623.460 1258:G04.299.134.500.320 1259:G04.299.134.109|ES| 19:1 94:1 263:1 299:1 303:1 304:1 438:1 552:1 601:1 615:1 849:1 2529:1 2948:1 3087:1 4430:1
-1 	|BT| (S (S (VP (TO To) (VP (VB approach) (NP (NN question))))) (, ,) (S (NP (JJ molecular) (JJ cellular) (NN response)) (VP (VBD monitored) (NP (NP (NP (NN development) (NN liver) (NN tumor) (NN mouse)) (VBN exposed) (NN chemical) (NN hepatocarcinogen)) (, ,) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drinking) (NN water)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN microg/l)) (-RRB- -RRB-))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 515:C04.588.274.623 554:D02.654.442.200 1060:D01.045.250.875.300 1260:E01.370.520|ES| 2:1 7:1 10:1 14:1 19:1 35:1 52:1 161:1 368:1 494:1 828:1 836:1 911:1 1875:1 1952:1 2124:1 3074:1 3102:1 3968:1 4295:1 4414:1 4431:1 4432:1 4433:1
-1 	|BT| (S (S (VP (TO To) (VP (VB clarify) (NP (NN mechanism) (NN IFN-alpha))))) (VP (VBZ prevents) (NP (NN hepatocarcinogenesis)) (, ,) (NP (NP (VBN examined) (NN effect) (NN IFN-alpha)) (VP (ADVP (RB chemically)) (VBN induced) (S (NP (NN hepatocarcinogenesis) (NN model)) (VP (VBD initiated) (SBAR (S (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN 2-AAF)) (-RRB- -RRB-))) (NP (JJ partial) (NN hepatectomy))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (VP (VBZ arises) (NP (JJ pre-neoplastic) (NN focus)) (PP (IN without) (NP (NN inflammation) (NN fibrosis))))))))))))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 525:C23.550.470 554:D02.654.442.200 691:C23.550.355 767:D02.065.064.150 881:D02.065.064.150 928:E04.210.556|ES| 2:1 10:1 14:1 19:1 72:1 75:1 162:1 303:1 304:1 324:1 412:1 441:1 828:1 900:1 949:1 1195:1 1431:1 1680:1 1875:1 1900:1 1912:1 1952:1 2581:1 2696:1 2718:1 3064:1 3193:1 3271:1 3272:1 3273:1 3525:1 4434:1
-1 	|BT| (S (S (VP (TO To) (VP (VB clarify)))) (, ,) (VP (VBD carried) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN experiment)) (S (VP (VBG using) (NP (JJ Cyp2e1-null) (NN mouse)))))) |ET| |BS|29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 247:G01.374.676.530 554:D02.654.442.200 1218:D08.244.453.300|ES| 2:1 19:1 52:1 350:1 828:1 900:1 2632:1 2732:1 3193:1 4435:1 4436:1
-1 	|BT| (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (JJ precise) (NN role) (NN UDCA) (NN chemoprevention) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (VBN examined) (NN expression) (NN level) (NN group) (CD II) (NN phospholipase) (NN A2)) (NP (JJ colonic) (NN tissue) (JJ UDCA-treated) (JJ untreated) (NN rat)))))) (VP (VBD correlated) (NP (NN level) (NN finding) (JJ aberrant) (NN crypt) (NN focus)) (, ,) (NP (JJ putative) (JJ preneoplastic) (NN lesion)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 52:E02 98:A10 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 253:E02.319.162 737:D04.808.105.225.272.962 824:C04.834.020 829:M01.686 1261:D08.811.277.352.100.680.750.937.750.550|ES| 2:1 19:1 31:1 113:1 115:1 207:1 249:1 272:1 324:1 439:1 446:1 644:1 677:1 828:1 849:1 870:1 918:1 927:1 1116:1 1131:1 1431:1 1438:1 1697:1 1725:1 2300:1 2533:1 2631:1 2913:1 4437:1 4438:1 4439:1
-1 	|BT| (S (S (VP (TO To) (VP (VB explore) (NP (NN role) (NN CHOP) (NN hepatocarcinogenesis))))) (, ,) (VP (VBD induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NP (NP (JJ wild) (NN type)) (PRN (-LRB- -LRB-) (NP (JJ wt)) (-RRB- -RRB-))) (NP (NP (NP (NP (NN CHOP) (NN knockout)) (PRN (-LRB- -LRB-) (NP (NN KO)) (-RRB- -RRB-))) (NP (NN mouse))) (S (VP (VBG using) (NP (NP (NN carcinogen) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))))) |ET| |BS|15:F01.829.316.616 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 279:D27.888.569.100 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 31:1 52:1 71:1 303:1 304:1 350:1 412:1 441:1 543:1 828:1 900:1 1875:1 1902:1 2125:1 2849:1 3231:1 4440:1 4441:1 4442:1
-1 	|BT| (S (VP (TO To) (FRAG (VB investigate) (NP (NP (NN effect) (NN Compound) (NN Astragalus)) (NP (FW Salvia) (FW miltiorrhiza) (NP (NP (NN Extract)) (PRN (-LRB- -LRB-) (NP (NN CASE)) (-RRB- -RRB-))) (NN diethylinitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN hepatocarcinogenesis) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780|ES| 10:1 14:1 19:1 75:1 409:1 459:1 828:1 849:1 900:1 1875:1 2492:1 2493:1 2494:1 2495:1 4103:1 4443:1 4444:1
-1 	|BT| (S (VP (TO To) (VP (VB shed) (NP (NP (JJ light) (JJ global) (NN change) (NN gene) (NN expression) (NN colon) (NN cancer) (NN gain) (NN insight) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (NP (NN colon) (NN carcinogenesis)) (, ,) (NP (VBN conducted) (NP (JJ comprehensive) (NN microarray) (NN analysis) (NN mRNA))) (VP (VBG using) (NP (NP (NN rat) (NN colon) (NN cancer) (NN model) (JJ food-borne) (NN carcinogen)) (, ,) (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 111:D13.444.735.544 155:G05.355.310 197:A01.456.505.420 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 425:G01.358.500.505.650 455:B01.050.150.900.649.147.890 680:G07.203.300 718:E05.588.570 744:D03.383.725 876:F01.145|ES| 2:1 9:1 10:1 14:1 18:1 19:1 72:1 113:1 115:1 161:1 162:1 200:1 207:1 325:1 350:1 435:1 660:1 661:1 828:1 849:1 913:1 964:1 1141:1 1337:1 1373:1 1378:1 1455:1 2125:1 2638:1 2639:1 2640:1 2641:1 3100:1 4445:1 4446:1
-1 	|BT| (S (S (VP (TO To) (VP (VB test) (NP (NN hypothesis))))) (, ,) (VP (VP (VBN studied) (NP (NP (NP (NP (NN effect) (NN Kupffer) (NN cell) (NN inhibition) (JJ dietary) (NN glycine)) (PRN (-LRB- -LRB-) (NP (NN inhibitor) (NN Kupffer) (NN cell) (JJ secretory) (NN activity)) (-RRB- -RRB-))) (NP (NN rat) (JJ two-stage) (NN hepatocarcinogenesis) (NN model))) (VP (VBG using) (NP (CD 2,2) ('' ')))) (NP (CD ,4,4) ('' ') (CD ,5,5) ('' '))) (: -) (PRN (NP (NN hexachlorobiphenyl) (-LRB- -LRB-) (NN PCB-153) (, ,) (JJ non-dioxin-like) (NN PCB)) (-RRB- -RRB-) (NP (NP (CD 3,3) ('' ') (CD ,4,4) ('' ')) (: -) (NP (NP (NP (NN tetrachlorobiphenyl)) (PRN (-LRB- -LRB-) (NP (NP (NN PCB-77)) (, ,) (NP (JJ dioxin-like) (NN PCB))) (-RRB- -RRB-))) (NN promoter)))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 1003:D12.125.481 1096:D03.383.231.900 1097:D03.383.231 1262:D02.065.277.727 1263:D02.455.426.559.389.185.698 1264:A11.329.372.588|ES| 2:1 10:1 14:1 19:1 72:1 75:1 83:1 94:1 103:1 350:1 380:1 399:1 401:1 643:1 828:1 849:1 900:1 1418:1 2594:1 2971:1 3045:1 4447:1 4448:1 4449:1 4450:1 4451:1 4452:1 4453:1 4454:1 4455:1
-1 	|BT| (S (NP (NN Tomato) (NN oleoresin)) (VP (VBZ inhibits) (NP (NN DNA) (NN damage) (JJ diethylnitrosamine-induced) (NN rat) (NN hepatocarcinogenesis)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 526:G05.355.180 554:D02.654.442.200|ES| 19:1 615:1 666:1 849:1 900:1 1848:1 2732:1 4456:1 4457:1
-1 	|BT| (NP (NP (NP (VBG Transforming) (NN growth) (NN factor-beta) (NN receptor) (NN type) (CD I)) (, ,) (NP (QP (CD II) (CD III)) (JJ phenobarbital-promoted) (NN rat) (NN liver) (NN tumor)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650|ES| 2:1 7:1 19:1 102:1 186:1 543:1 836:1 849:1 1116:1 1773:1 2281:1 2350:1 3877:1 4458:1
-1 	|BT| (S (NP (NN Treatment) (NN HCC) (NN colon) (NN cancer) (NN xenograft) (NN aspirin) (NN sorafenib)) (VP (VBP result) (NP (JJ significant) (NN tumor) (NN suppression) (JJ single) (NN agent)))) |ET| |BS|8:C04 52:E02 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 670:D02.455.426.559.389.657.410.595.176 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 7:1 18:1 19:1 101:1 113:1 135:1 265:1 441:1 728:1 2063:1 2453:1 2487:1 2846:1 3106:1
-1 	|BT| (NP (NP (NN Vanadium) (JJ chemopreventive) (JJ early) (NN stage) (JJ 2-AAF-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 837:D01.268.556.920 881:D02.065.064.150|ES| 19:1 849:1 900:1 1128:1 1129:1 1946:1 3124:1 3125:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (NN panel) (CD 12) (NN gene)) (VP (VBD upregulated) (NP (NP (CD three) (NN class) (NN liver) (NN tumor)) (, ,) (ADJP (ADVP (RB namely)) (X (SYM AOX)) (: -) (: /) (: -) (, ,) (JJ ciprofibrate-induced) (JJ DENA-induced)))))))) |ET| |BS|149:G05.360.340.024.340.364.875.890 515:C04.588.274.623 554:D02.654.442.200|ES| 2:1 7:1 9:1 19:1 37:1 125:1 482:1 510:1 836:1 843:1 1120:1 2814:1 3026:1 4321:1 4324:1 4459:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD assessed) (NP (NP (NP (NP (NP (JJ chemopreventive) (NN property) (NN NO-indomethacin)) (PRN (-LRB- -LRB-) (NP (NN NCX) (CD 530)) (-RRB- -RRB-))) (NN NO-aspirin)) (PRN (-LRB- -LRB-) (NP (NN NCX) (CD 4016)) (-RRB- -RRB-))) (JJ azoxymethane-induced) (NN colon) (NN cancer)))) |ET| |BS|132:D02.172.080 795:D03.438.473.420|ES| 10:1 14:1 18:1 19:1 113:1 841:1 843:1 1946:1 2533:1 3823:1 4460:1 4461:1 4462:1 4463:1 4464:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP conclude) (SBAR (S (SBAR (IN although) (S (NP (NN PB) (CD 2) (NNS conazoles)) (VP (VBP induce) (NP (NN mouse) (NN liver) (NN tumor))))) (VP (VBP exhibit) (NP (NP (JJ similar) (JJ toxicological) (NN response)) (, ,) (NP (JJ transcriptional) (NN profile))) (ADJP (RB significantly) (JJ different)) (NP (ADVP (NP (RB thus) (NN mechanism) (JJ tumorigenic) (NN action)) (JJ likely)) (VBP differ))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 175:J01.897.280.500.269 209:G02.111.087.847 515:C04.588.274.623 557:D02.241.081.069.600.150 742:G03.787 1265:H01.158.891|ES| 2:1 7:1 19:1 52:1 124:1 148:1 162:1 243:1 332:1 414:1 494:1 559:1 587:1 836:1 843:1 1328:1 1334:1 1592:1 1711:1 1809:1 1968:1 2013:1 3496:1 3497:1 4465:1 4466:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP conclude) (SBAR (S (NP (JJ Cyp2e1-null) (NN mouse)) (VP (VBP show) (SBAR (S (NP (JJR lower) (NN tumor) (NN incidence) (NN multiplicity)) (VP (VBN compared) (NP (JJ wild-type) (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 434:E05.318.308.985.525.375 554:D02.654.442.200 557:D02.241.081.069.600.150 1218:D08.244.453.300|ES| 7:1 8:1 19:1 50:1 52:1 117:1 429:1 843:1 900:1 1511:1 1968:1 2732:1 2863:1 4436:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP find) (SBAR (S (JJ enzastaurin) (ADVP (RB potently)) (VP (VBZ reduces) (NP (NP (JJ azoxymethane-induced) (NN colon) (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (JJ PKCbetaII-mediated) (NN tumor) (NN cell) (NN proliferation) (NN beta-catenin) (NN accumulation))))))))) |ET| |BS|8:C04 16:C23.550.291.656 23:D12.776.091.249 51:C04.588.274.476.411.307.180 122:C14.280.383 132:D02.172.080 183:G04.299.233.750 866:D08.811.913.696.620.682.700.725.049|ES| 7:1 19:1 48:1 60:1 94:1 113:1 142:1 299:1 637:1 843:1 880:1 2120:1 2533:1 2855:1 3127:1 3128:1 3129:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD induced) (SBAR (S (NP (NN liver) (NN tumor) (NN mouse) (NN treatment) (NN liver) (NN carcinogen) (NN N-nitrosodiethylamine)) (VP (VBD followed) (NP (NP (JJ chronic) (NN treatment) (NN tumor) (NN promoter)) (NN phenobarbital))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 242:A03.620 279:D27.888.569.100 515:C04.588.274.623 554:D02.654.442.200 600:D27.888.569.100 756:D03.383.742.698.253.650|ES| 7:1 19:1 52:1 83:1 412:1 546:1 836:1 843:1 1790:1 2125:1 2602:1 2685:1 3130:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD reported) (SBAR (S (NP (JJ brief) (NN exposure) (JJ pregnant) (NN C3H) (NN mouse) (NN arsenite) (NN drinking) (NN water) (NN gestation)) (VP (VBD induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ male) (NN offspring)) (VP (VBD became) (ADJP (JJ adult))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 119:M01.060.116 1060:D01.045.250.875.300 1154:B01.050.050.199.520.520.388 1155:G08.686.340 1266:G08.686.785.760.769|ES| 10:1 14:1 19:1 52:1 303:1 304:1 355:1 412:1 441:1 843:1 993:1 1402:1 1953:1 3968:1 3999:1 4000:1 4001:1 4003:1 4295:1 4467:1 4468:1 4469:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD monitored) (SBAR (S (NP (JJ pre-neoplastic) (NN focus)) (VP (VBD induced) (NP (JJ two-stage) (NN initiation/promotion) (NN model) (NN hepatocarcinogenesis) (NN rat)) (, ,) (S (VP (VBG using) (NP (NN diethylnitrosamine) (NN acetylaminofluorene))))))))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 881:D02.065.064.150 1260:E01.370.520|ES| 2:1 19:1 72:1 350:1 412:1 843:1 849:1 900:1 1431:1 1952:1 2971:1 3525:1 4432:1 4470:1 4471:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (S (NP (NP (NN role) (NN PBP/MED1) (JJ genotoxic) (NN chemical) (NN carcinogen) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (JJ phenobarbital-promoted) (NN hepatocarcinogenesis)))))) |ET| |BS|15:F01.829.316.616 279:D27.888.569.100 554:D02.654.442.200 756:D03.383.742.698.253.650 1105:D05.500.374.750|ES| 10:1 14:1 19:1 31:1 324:1 409:1 843:1 900:1 1875:1 1952:1 2124:1 2125:1 3329:1 4458:1 4472:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (ADVP (RB strongly)) (VP (VBZ enhances) (SBAR (S (NP (NP (NP (NN colon) (NN carcinogenesis) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN over-expression) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-)))) (VP (VBZ contributes) (NP (NN enhancement)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 22:D08.811.682.664.500.772.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300|ES| 10:1 14:1 19:1 52:1 63:1 64:1 65:1 66:1 67:1 113:1 207:1 280:1 406:1 407:1 635:1 705:1 843:1 845:1 993:1 1013:1 1356:1 1527:1 2278:1 3300:1 3306:1
-1 	|BT| (FRAG (NP (PRP We)) (ADVP (RB recently)) (VBD showed) (NP (NP (JJ high-fat) (NN diet)) (PRN (-LRB- -LRB-) (NP (NN HFD)) (-RRB- -RRB-))) (: -) (VBN induced) (NP (NP (JJ nonalcoholic) (NN steatohepatitis)) (PRN (-LRB- -LRB-) (NP (NN NASH)) (-RRB- -RRB-))) (VBD promoted) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN initiated) (NN hepatocarcinogenesis) (NN rat) (NN model))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 554:D02.654.442.200 694:G07.203.650.240.267|ES| 10:1 14:1 19:1 72:1 132:1 409:1 772:1 843:1 849:1 900:1 1791:1 1796:1 1875:1 1912:1 1952:1 2191:1 2507:1 3065:1 4024:1 4473:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD studied) (NP (NP (NN mechanism) (VBG underlying) (NN inhibition) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NN lycopene) (NN rat)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 10:1 14:1 19:1 103:1 162:1 401:1 409:1 435:1 843:1 849:1 900:1 1875:1 1952:1 2566:1
-1 	|BT| (S (NP (PRP We)) (VBD studied) (SBAR (IN whether) (S (NP (NP (JJ abundant) (JJ mutagenic) (JJ heterocyclic) (NN amine)) (VP (VBN isolated))) (VP (VBD cooked) (NP (NP (NN food)) (, ,) (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (, ,))))) (VP (MD could) (VP (VB influence) (NP (NP (JJ early) (JJ intestinal) (NN neoplasia) (NN C57BL/6J-Min)) (: /) (NP (CC +) (NN C57BL/6J) (: -) (CC +) (: /) (CC +) (PRN (-LRB- -LRB-) (ADJP (JJ wild-type)) (-RRB- -RRB-)) (NN mouse) (NN sex)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 593:B01.050.050.199.520.520.420 680:G07.203.300 744:D03.383.725 856:D02.092 1082:J01.576.423.200.200 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810 1267:D27.888.569.468|ES| 2:1 8:1 10:1 14:1 19:1 51:1 52:1 109:1 221:1 401:1 640:1 843:1 867:1 908:1 1128:1 1373:1 1378:1 1653:1 1798:1 2470:1 2638:1 2639:1 2640:1 2641:1 3054:1 3798:1 4088:1 4474:1 4475:1 4476:1 4477:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD compared) (SBAR (S (SYM AOX) (: -) (NP (: /) (: -) (NN liver) (NN tumor) (NN expression) (NN profile)) (VP (VBD induced) (SBAR (S (NP (NP (NN ciprofibrate)) (, ,) (NP (JJ non-genotoxic) (NN peroxisome) (NN proliferator)) (, ,) (NP (NP (JJ genotoxic) (NN carcinogen) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DENA)) (-RRB- -RRB-)))) (VP (VBP discern) (SBAR (S (NP (NN difference) (NN gene) (NN expression) (NN pattern)) (VP (MD may) (VP (VB predict) (VP (VB distinguish) (NP (JJ PPARalpha-mediated) (NN liver) (NN tumor)) (VP (ADVP (RB genotoxically)) (VBN derived) (S (NP (NN tumor))))))))))))))))) |ET| |BS|155:G05.355.310 279:D27.888.569.100 515:C04.588.274.623 536:D12.776.826.239.500 554:D02.654.442.200 912:D27.888.569.100.675|ES| 2:1 7:1 9:1 10:1 14:1 19:1 50:1 115:1 260:1 412:1 491:1 836:1 843:1 1302:1 1674:1 1711:1 1721:1 1887:1 1888:1 1952:1 2125:1 3329:1 4049:1 4321:1 4413:1 4478:1 4479:1 4480:1 4481:1 4482:1
-1 	|BT| (S (NP (PRP We)) (RB thus) (NP (NP (NP (JJ treated) (JJ simple) (NN Tgfbr2)) (PRN (-LRB- -LRB-) (NP (NN DeltaIEC)) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (VP (VBP cause) (NP (JJ ulcerative) (NN colitis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 73:N05.715.350.200 131:D09.698.365.272.300 1268:C06.405.205.265.231|ES| 10:1 14:1 19:1 52:1 143:1 406:1 407:1 843:1 1099:1 1334:1 1779:1 3300:1 3306:1 4347:1 4483:1 4484:1 4485:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD used) (S (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN injection) (NN initiate) (NN liver) (NN cancer) (NN mouse)) (NP (VBN assessed) (NN extent) (NN liver) (NN cancer) (JJ JDP2-transgenic) (JJ wild) (NN type) (NN control) (NN mouse) (JJ biochemical) (JJ molecular) (NN biology) (NN technique))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 352:B01.050.050.136 554:D02.654.442.200 1269:H01.158.201.636|ES| 10:1 14:1 18:1 19:1 52:1 161:1 289:1 476:1 543:1 785:1 836:1 843:1 1689:1 1875:1 1952:1 3595:1 3823:1 4442:1 4486:1 4487:1 4488:1 4489:1
-1 	|BT| (S (NP (SBAR (WHADVP (WRB When)) (S (NP (NN goldenseal)) (VP (VBD evaluated) (NP (NNP National) (NNP Toxicology) (NNP Program))))) (PRN (-LRB- -LRB-) (NP (NNP NTP)) (-RRB- -RRB-)) (NP (JJ standard) (JJ 2-year) (NN bioassay)) (, ,) (NP (NP (NN goldenseal)) (VP (VBD induced) (NP (NN increase) (NN liver) (NN tumor) (NN rat) (NN mouse)))) (: ;)) (ADVP (RB however)) (, ,) (NP (NN mechanism) (JJ goldenseal-associated) (NN liver) (NN carcinogenicity)) (VP (VBZ remains) (ADJP (JJ unknown)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 106:E05.091 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 515:C04.588.274.623 1265:H01.158.891 1270:B01.650.940.800.575.100.838.397 1271:E05.337.820|ES| 2:1 7:1 10:1 14:1 19:1 40:1 52:1 162:1 217:1 412:1 442:1 780:1 836:1 849:1 1387:1 2182:1 2292:1 2931:1 3583:1 4178:1 4490:1 4491:1 4492:1 4493:1 4494:1 4495:1 4496:1
